The Tim Ferriss Show - #517: Dr. Peter Attia on Longevity Drugs, Alzheimer's Disease, and the 3 Most Important Levers to Pull
Episode Date: June 9, 2021Brought to you by Athletic Greens all-in-one nutritional supplement and Eight Sleep’s Pod Pro Cover sleeping solution for dynamic cooling and heating. Dr. Peter Att...ia (PeterAttiaMD.com) is a former ultra-endurance athlete (e.g., swimming races of 25 miles), a compulsive self-experimenter, and one of the most fascinating human beings I know. He is one of my go-to doctors for anything performance or longevity-related.But here is his official bio to do him justice:Peter is a physician focusing on the applied science of longevity. His practice deals extensively with nutritional interventions, exercise physiology, sleep physiology, emotional and mental health, and pharmacology to increase lifespan (how long you live), while simultaneously improving healthspan (how well you live).Peter trained for five years at the Johns Hopkins Hospital in general surgery, where he was the recipient of several prestigious awards, including Resident of the Year, and the author of a comprehensive review of general surgery. He also spent two years at NIH as a surgical oncology fellow at the National Cancer Institute where his research focused on immune-based therapies for melanoma. He has since been mentored by some of the most experienced and innovative lipidologists, endocrinologists, gynecologists, sleep physiologists, and longevity scientists in the United States and Canada.Peter earned his M.D. from Stanford University and holds a B.Sc. in mechanical engineering and applied mathematics.Peter also hosts The Drive, a weekly, deep-dive podcast focusing on maximizing longevity and all that goes into that, from physical to cognitive to emotional health. It features topics including fasting, ketosis, Alzheimer’s disease, cancer, mental health, and much more. Subscribe on Apple Podcasts, Spotify, Overcast, or wherever you listen to podcasts.Please enjoy!This episode is brought to you by Athletic Greens. I get asked all the time, “If you could only use one supplement, what would it be?” My answer is usually Athletic Greens, my all-in-one nutritional insurance. I recommended it in The 4-Hour Body in 2010 and did not get paid to do so. I do my best with nutrient-dense meals, of course, but AG further covers my bases with vitamins, minerals, and whole-food-sourced micronutrients that support gut health and the immune system. Right now, Athletic Greens is offering you their Vitamin D Liquid Formula free with your first subscription purchase—a vital nutrient for a strong immune system and strong bones. Visit AthleticGreens.com/Tim to claim this special offer today and receive the free Vitamin D Liquid Formula (and five free travel packs) with your first subscription purchase! That’s up to a one-year supply of Vitamin D as added value when you try their delicious and comprehensive all-in-one daily greens product.*This episode is also brought to you by Eight Sleep! Eight Sleep’s Pod Pro Cover is the easiest and fastest way to sleep at the perfect temperature. It pairs dynamic cooling and heating with biometric tracking to offer the most advanced (and user-friendly) solution on the market. Simply add the Pod Pro Cover to your current mattress and start sleeping as cool as 55°F or as hot as 110°F. It also splits your bed in half, so your partner can choose a totally different temperature.And now, my dear listeners—that’s you—can get $250 off the Pod Pro Cover. Simply go to EightSleep.com/Tim or use code TIM. *If you enjoy the podcast, would you please consider leaving a short review on Apple Podcasts/iTunes? It takes less than 60 seconds, and it really makes a difference in helping to convince hard-to-get guests. I also love reading the reviews!For show notes and past guests, please visit tim.blog/podcast.Sign up for Tim’s email newsletter (“5-Bullet Friday”) at tim.blog/friday.For transcripts of episodes, go to tim.blog/transcripts.Discover Tim’s books: tim.blog/books.Follow Tim:Twitter: twitter.com/tferriss Instagram: instagram.com/timferrissFacebook: facebook.com/timferriss YouTube: youtube.com/timferrissPast guests on The Tim Ferriss Show include Jerry Seinfeld, Hugh Jackman, Dr. Jane Goodall, LeBron James, Kevin Hart, Doris Kearns Goodwin, Jamie Foxx, Matthew McConaughey, Esther Perel, Elizabeth Gilbert, Terry Crews, Sia, Yuval Noah Harari, Malcolm Gladwell, Madeleine Albright, Cheryl Strayed, Jim Collins, Mary Karr, Maria Popova, Sam Harris, Michael Phelps, Bob Iger, Edward Norton, Arnold Schwarzenegger, Neil Strauss, Ken Burns, Maria Sharapova, Marc Andreessen, Neil Gaiman, Neil de Grasse Tyson, Jocko Willink, Daniel Ek, Kelly Slater, Dr. Peter Attia, Seth Godin, Howard Marks, Dr. Brené Brown, Eric Schmidt, Michael Lewis, Joe Gebbia, Michael Pollan, Dr. Jordan Peterson, Vince Vaughn, Brian Koppelman, Ramit Sethi, Dax Shepard, Tony Robbins, Jim Dethmer, Dan Harris, Ray Dalio, Naval Ravikant, Vitalik Buterin, Elizabeth Lesser, Amanda Palmer, Katie Haun, Sir Richard Branson, Chuck Palahniuk, Arianna Huffington, Reid Hoffman, Bill Burr, Whitney Cummings, Rick Rubin, Dr. Vivek Murthy, Darren Aronofsky, and many more.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Transcript
Discussion (0)
This episode is brought to you by Eight Sleep. My God, am I in love with Eight Sleep. Good sleep
is the ultimate game changer. More than 30% of Americans struggle with sleep, and I'm a member
of that sad group. Temperature is one of the main causes of poor sleep, and heat has always been my
nemesis. I've suffered for decades tossing and turning, throwing blankets off, putting them back
on, and repeating ad nauseum. But now I am falling asleep in record
time faster than ever. Why? Because I'm using a simple device called the Pod Pro Cover by 8sleep.
It's the easiest and fastest way to sleep at the perfect temperature. It pairs dynamic cooling and
heating with biometric tracking to offer the most advanced but most user-friendly solution on the market. I polled all of you
guys on social media about the best tools for sleep, enhancing sleep, and 8sleep was by far
and away the crowd favorite. I mean, people were just raving fans of this. So I used it,
and here we are. Add the Pod Pro Cover to your current mattress and start sleeping as cool as
55 degrees Fahrenheit or as cool as 55 degrees Fahrenheit
or as hot as 110 degrees Fahrenheit.
It also splits your bed in half so your partner can choose a totally different temperature.
My girlfriend runs hot all the time.
She doesn't need cooling.
She loves the heat.
And we can have our own bespoke temperatures on either side, which is exactly what we're
doing.
Now, for me and for many people, the result,
eight sleep users fall asleep up to 32% faster, reduce sleep interruptions by up to 40% and get
more restful sleep overall. I can personally attest to this because I track it in all sorts
of ways. It's the total solution for enhanced recovery. So you can take on the next day feeling
refreshed. And now my dear listeners, that's you guys. You can get $250 off of the Pod
Pro cover. That's a lot. Simply go to 8sleep.com slash Tim or use code Tim. That's 8, all spelled
out E-I-G-H-T, sleep.com slash Tim, or use coupon code Tim, T-I-M, 8sleep.com slash TIM for $200 off your Pod Pro cover.
This episode is brought to you by Aura, O-U-R-A. It is the only wearable that I wear on a daily
basis. Aura is the company behind the Smart Ring that delivers personalized sleep and health
insights to help you optimize just about everything.
And I've tried every device out there that you can imagine.
This one really makes the cut.
I've been using it religiously for at least six months now,
and I was introduced to it by Dr. Peter Attia, who's also vetted just about everything.
With advanced sensors, AuraPack's state-of-the-art heart rate, heart rate variability,
HRV, super important to
me, temperature activity, and sleep monitoring technology into a convenient non-invasive ring.
It's tiny. It weighs less than six grams and focuses on three key insights, sleep, readiness,
and activity. So I can use it to help focus my attention on the type, volume, intensity of
exercise that I should do in a given day.
I use it to determine how certain types of alcohol at different times of the day affect my sleep, which they do. And I can see all of that in graph form trended over time.
There are tons of actionable insights that have come from using this ring for me. They have a
number of incredible people on their team. Dr. Matthew Walker, a professor of neuroscience and
psychology at UC Berkeley, and also author of Why We Sleep, the mega hit, is Aura's chief science
advisor as just one example. The Aura Ring is one of the most accurate wearables available because
it measures your vitals directly from your finger. So it's not deducing that or making a best guesstimate based on a bunch of other things
and trying to triangulate. Compared to a medical grade electrocardiogram, the Oura Ring is 99.9%
accurate for resting heart rate and 98.4% accurate for heart rate variability. And I work with HRV
doctors and they recommend that I use the Oura Ring. So try it yourself. It is super cool and super practical, very actionable.
The Aura Ring comes in two styles and three colors,
silver, black, and matte black.
I use matte black.
For $299, you can give or get the gift of health
by visiting auraring.com.
That's O-U-R-A-R-I-N-G.com. Again, that's OuraRing.com. I'm a cybernetic organism living tissue over metal endoskeleton. The Tim Ferriss Show.
Hello boys and girls, ladies and germs. This is Tim Ferriss and welcome to another episode of the Tim Ferriss Show.
This is a very special edition. I am in the cave of Peter Attia, Dr. Peter Attia.
And we'll get back to his bio in a second. We have the
incredible videographer who is trapped inside a closet to monitor levels. Everything has been
fitted to perfection. And that all makes sense shortly. Dr. Peter Attia, who can be found at
peterattiamd.com, is a former ultra endurance athlete. So imagine swimming races of 25 or so miles, maybe more,
a compulsive self-experimenter, emphasis on compulsive, and one of the most fascinating
human beings I know. He is one of my go-to doctors. I would say the go-to doctor for me,
for anything performance or longevity related. But here's the official bio to do him some justice.
Peter is a physician focusing on the applied science of longevity. His practice deals extensively with nutritional interventions, exercise physiology, sleep
physiology, emotional and mental health, and pharmacology to increase lifespan, that is how
long you live, while simultaneously improving healthspan. In other words, how well you live.
Peter trained for five years at the Johns Hopkins Hospital in General Surgery, where he was the
recipient of several prestigious awards, including Resident of the Year and
the author of a comprehensive review of general surgery.
He also spent two years at NIH as a surgical oncology fellow at the National Cancer Institute,
where his research focused on immune-based therapies for melanoma.
He has since been mentored by some of the most experienced and innovative lipidologists, endocrinologists, gynecologists, sleep physiologists, and longevity scientists in the United States and Canada.
Peter earned his MD from Stanford University and holds a Bachelor's of Science in Mechanical Engineering and Applied Mathematics.
Last but not least, and this would explain the immaculate video and audio setup that I am enjoying today. Peter also hosts
The Drive, a weekly deep dive podcast. And I do mean deep dive, focusing on maximizing longevity
and all that goes into that, including physical, cognitive, and emotional health. It features
topics including fasting, ketosis, Alzheimer's disease, cancer, mental health, and much more.
You can subscribe on Apple Podcasts, Spotify, Overcast, or wherever you listen to podcasts. You can find him all over the interwebs,
peteratiamd.com, on Twitter, at peteratiamd, Instagram, same, same, peteratiamd, Facebook,
you got it, peteratiamd, and then on YouTube, peteratiamd. Peter, welcome back to the show. Wow, that was quite an intro.
It was an incredibly comprehensive intro.
I could have shown up a little later for this.
So we've had frequent flyer miles on podcasts, including on this show. And last time we used
a format that I quite enjoyed in part because it required minimal preparation for me. And that
was going through categories, excited about, changed mind about, and stupid things or absurd
things that you do. And I know that you have a number of things that you are excited about.
So we may spend more time in that category. So why don't you kick us off? However you like.
So yeah. So the nice thing about this is I get to prepare a little bit and I jotted down a few bullet points on each. So I
think one of the things I'm really excited about is a very recent thing in that it's come to market
really recently. It's been in the works for about five years and it's something called a liquid
biopsy. And the reason this is interesting is that when you think about the sort of major chronic
diseases, which is the diseases of atherosclerosis, so heart disease, stroke, cancer, and Alzheimer's
disease, we don't have a lot of great tools at detecting cancer early. So cancer screening
is a somewhat controversial topic. Most people are probably familiar with things like mammograms,
colonoscopies, and PSA testing. There are two or three others that rise to the level of
having evidence to suggest that we do them, for example, pap smears. But when it comes to some of
the really bad actors of cancer, we don't really have great screening tools. And so what a liquid
biopsy does is it draws a sample of blood and through that tries to predict whether or not you
have cancer cells in your body and tries to do so, of course, when you have very, very few of them, because the evidence is
overwhelming that all things being equal, a cancer when caught early, at an early stage,
is imminently more curable than a cancer caught at a later stage. And probably the most compelling
explanation for that is that the longer a cancer gets to fester in your body, the more chance it
has to develop mutations, and the more mutations it generates, the more
difficult it is to target later on. So there are a number of companies that have been doing this,
but to me, the most interesting by far is a company called Grail because of the method that
they've gone about doing this. And the method is using something called cell-free DNA as opposed to
tumor DNA. And just for those listening, Grail as in Holy Grail. Exactly. Coming out big.
As a little side note, Grail was recently acquired by another company called Illumina,
Illumina being the largest company that does DNA sequencing. And a very interesting note is the FTC has sued
Illumina for antitrust violations in this acquisition, which if you understand the
science of it, and we don't have to get into it in great detail, is literally the dumbest thing
I've ever heard. So that the FTC has done this, in my opinion, is actually a tragedy because it
is actually going to cost lives. It's going to cost tens of thousands of lives in delay if this acquisition does not go through because Illumina has the power
to scale this up like no other company would. Putting that aside for a moment, what is cell
free DNA? Because that's really at the heart of this technology. Say that one more time.
What is cell free DNA? Cell free DNA. Like C-E-L-L hyphen free. Yeah, as in DNA that's not
in a cell. So most of dna in your body is contained
within cells but when a cell breaks down or sometimes even when cells spontaneously like
red blood cells or actually typically monocytes white blood cells make dna and then spontaneously
release it from them you can capture these small amounts of cell-free dna so if you draw somebody's
blood whether or not they have cancer or not they're going to have a certain amount of this cell-free DNA floating
around. You have signatures on DNA called methylations. So a methyl group is just a
carbon with three hydrogens on it. It's one of the most basic building blocks of organic chemistry.
And as DNA acquires these signatures, so remember DNA is made up of these four nucleotides,
when they start binding these little methyl groups-
That's the ACTG.
Exactly, ACTG. As they start acquiring these methyl groups, that tells a bit of a story.
And even though there's not a lot of cell-free DNA, when you look at it, the best analogy,
and one of my analysts actually came up with this analogy, is it's sort of like looking at meteor fragments that would land in the desert and being able to understand what type of an asteroid they came from.
So even though the asteroid is enormous and it shed big chunks of meteor down to Earth, and by the time they actually hit the Earth, they're just small rocks, a chemical analysis of that would give you a greater idea where it came from.
So this type of test can actually detect up to 50 different types of cancers. There are certain
ones that it's not very good at detecting, such as prostate cancer, which is not bad because we
have other tools that are so good at detecting prostate cancer. But when you do this blood test,
you basically get a readout which says no cancer detected or the following have been detected. And it does this with about a 50%
sensitivity and about a 97 to 99% specificity. Now to explain what that means in context
requires a little bit of math and it's worth going into. So sensitivity is the probability
that a cancer is truly there if detected by the test. And specificity is the probability that a cancer is truly there if detected by the test, and specificity is the
probability that the cancer is not there if not detected by the test. So sensitivity speaks to
true positives and specificity speaks to true negatives. Now at first, 50% sensitivity doesn't
sound that good, but you have to remember it depends on what we call the pre-test probability
is. So pre-test probability says, what is the probability that you have cancer before I test
you? And that's a function of many things. It's a function of the prevalence of that cancer.
It's a function of your age. It's a function of other behaviors. So for example, two people being
otherwise identical, except one being a smoker and one not being a smoker, are going to have
very different pre-test probabilities. But when you start to think about, for example, you,
what's your pre-test probability of having pancreatic cancer? It's quite low, fortunately,
even though pancreatic cancer is one of the most lethal cancers out there. So in a low probability
environment, a modest sensitivity of 50% and a very high specificity produces incredible,
what we call positive and negative predictive value. So what do those things mean? So positive
predictive value, as it sounds, means what's the probability that if you get a positive test,
you truly have cancer. A negative predictive value is, of course, if you have a negative test,
what's the probability it's negative? These numbers end up being well north of 90 percent in fact the negative predictive value is about 99.7 percent
the positive predictive value is in the ballpark of about 97 percent. So these are really exciting
tests especially when you pair them with some of the other things that we do in our practice
such as relying on a very special type of MRI technology that uses something called
diffusion-weighted imaging that adds sort of a functional dimension to MRI.
Quick note there, people can, if they really want to deep dive into that subject matter,
you have a guest on your podcast. And I've listened to this episode. It does get quite
technical, but what is the guest's name for people who want to search? Raj, R-A-J,
and how do you spell his last name? A-T-T-R-A-A-W-A-L. Of course, I can't spell in my
head, but if you just search Raj MRI, it'll pop up. And yes, that's an episode we usually make
our patients listen to before they go and get one of those MRIs so they understand it. Follow up to that, unrelated but related to Grail, what is it that happened or what technology was
developed that suddenly made this possible where it was not possible before? Or what realization,
why did this suddenly come to fruition or only now become available?
I think the major insight, and I will be doing a podcast on this,
but I need to wait until this FTC issue is resolved a little bit because the person that
I really want to interview for the podcast, who is one of the people that had the biggest hand
in developing this, is actually now the chief scientific officer at Illumina. So for him to
be able to speak about it, obviously it would need to make sense that Illumina actually owns
the technology again. I would say, and this might change as I get deeper into understanding
their journey I think it was the realization that tumor DNA was not the place to go so at the outset
of this process people didn't know what to look for would you look for RNA of tumors because RNA
is the template that's telling you to make the protein. And that didn't really
pan out because RNA is so unstable by itself. So then pivoting to DNA, the logical choice was,
well, let's look for the tumor DNA. If you have pancreatic cancer and we can find the DNA of a
pancreatic cancer cell, that would be a good place to start. But you have to be looking for cell-free
DNA by definition when you're doing a liquid
biopsy because you're not going to sample the organ. And it turns out that tumor DNA represents
about 0.1% of cell-free DNA. So I think the big aha for Grail was realizing, no, let's look at
cell-free DNA, which is much more abundant, but instead look at the methylation patterns and then
specifically figure out what those methylation patterns were. So that was the real puzzle. Yeah. The forensic science.
That's very cool. I don't know if I interrupted a train of thought that had more to say about
Grail. Do you want to say more about Grail or do you want to hop to another?
Yeah, no. I mean, I just think that this is, I have been waiting for this, like I said, for five years, because I think that I'm just less
bullish on the idea that we're going to quote unquote cure cancer, right? If you put cancer
in perspective, the overall survival for people with metastatic cancer has improved about 5% in
50 years. And virtually all of that improvement has come with a handful of
very specific types of cancers. For example, something called the GI stromal tumor and a
certain type of testicular cancer for which there's been like very specific behaviors of
these that have rendered them quite sensitive to certain chemotherapies. But when it comes to,
you know, lung cancer, when it comes to pancreatic cancer, when it comes to lung cancer, when it comes to pancreatic
cancer, when it comes to colon cancer, breast cancer, once you don't catch it early, you're
sort of in the same situation you were in in about 1970. That's pretty depressing when you consider
how much progress has been made in cardiovascular disease since that time. So I think the answer
in how do you live longer with respect to cancer is prevention.
Well, it's both, right?
So what can we do to prevent cancer?
And not smoking and being metabolically healthy are hands down the two biggest things that
you can do.
And then the next step is how aggressively can you screen and stack different levels
of screening technologies on top of each other so that the way we kind of describe it to
patients is you want to think of like the swiss cheese approach right you want to be able to stack
a whole bunch of things on top of themselves so that you just get only one pencil can fit through
yeah each method or technology in of itself having gaps but when you lay them on top of each other
hopefully the remaining gaps are sort of allowable if that makes any sense absolutely
and it's exactly that it's basically how do you use multiple technologies to cover the blind spots
of others i'm excited about grail also because it seems like especially if scaled through alumina
the ability to have grail widely distributed makes it just by definition more available, at least as one tool compared to say
the MRI that we were referring to earlier, which would appear to be site specific. I don't know.
Yeah. MRI is going to be far less scalable and frankly, far more of a hassle. I mean,
if you've, I don't know if you've ever had, well, you haven't had one yet. We got to get you up
there. I've had for better and for worse, probably quite a few MRIs, not always in ideal circumstances,
but this particular MRI, not yet.
Yeah.
So it's like, how do you drive the cost down?
How do you improve the technology?
How do you make the algorithm better and better and better?
Because it is, under all of this, is a huge engine of machine learning that makes it better
over time.
So you mentioned, in terms of prevention, metabolically healthy.
Is there anything you're excited about or would
like to underscore that relates to developing metabolic health or improving metabolic health?
Always. I'd say exercise is so important, right? It can't be overstated. It's potentially one of
the most potent drugs we have.
But all exercise is not created equal, I would imagine.
Correct.
For this purpose.
Absolutely. And so I think of exercise as having four pillars. You have to be strong on each of
those. So if you're strong in three but not in one, it's sort of like a table that has three
legs and not one. It's still a reasonable table, but it's not as strong as a table with four legs. And a table with two legs is pretty
pathetic. And obviously a table with one leg is not a table. So the four pillars are stability,
strength, aerobic efficiency, and anaerobic performance. And I think that most people
understand loosely what three of those are. Can you say those all one more time?
Sure. Stability. That's the those all one more time? Sure.
Stability. That's the one that most people don't understand. We can talk about that in a minute.
Strength, aerobic efficiency, and anaerobic performance. So I guess we can unpack all of
them, but stability is the ability to safely transfer load from the outside world to the body and vice versa, which sounds
sort of like a soft explanation. An analogy that I really like using is that of a race car versus
a street car. So what makes race cars so unique is that, and why, by the way, a race car that's
got half the power of a street car will still knock its socks off on a track is because the chassis and the tires of the race car are constructed in such a way that every
bit of that power is making it to the road. So the analogy I like to think of is that the tires of a
race car are like our feet and stability really does begin with the feet. And most people, myself
included, when I was starting had horrible proprioception with
our feet. You know, we don't really know how to load our feet correctly. And a lot of that
comes from the fact that we wear shoes all day. Your hands and your feet are actually very similar.
And if you think about what you can do with your hands, how easily you can move them around,
spread your fingers, sense pressure in different areas, most people can't do that with their feet.
And that comes to
bite you. So as you think about how it moves up the sort of chain, a very common problem is,
which I think accounts for probably more of the injuries that people experience,
is this pattern where the pelvis is tilted forward, the ribs are flared up, the erector
spinae muscles in the back are sort of locked short meaning
they're locked in concentric load and the hamstrings are locked long so they're locked
in eccentric load yeah it's how someone who's quite lean from a body fat perspective can still
look like they have a pot belly that's right with that anterior pelvic tilt which actually so you've
asked me a question i think i can answer this, there are really two things I'm excited about that pertain to exercise.
And I'll go down this path and then we'll come back to the other one.
What's the etiology of that position, which I was the king of that position?
It's probably...
What do you mean by etiology?
Like what drives that?
Why would a person show up with that posture of ribs flared up
pelvis tilted forward back tight hamstrings tight and long besides wearing six inches the
little heels which i never wore i mean i wore them sometimes but i don't often wear them you're in
good company jen grahoover and all continue so it probably starts with lousy respiration and i'm not exactly sure why that's the case but
i think somewhere along the way we stop breathing correctly into our abdomen instead of breathing
the way we should breathe which is the diaphragm should go down the abdomen should come out the
pelvis should actually fill with pressure we tend to breathe using so that's the those are the
primary muscles of respiration as
a diaphragm we start using accessory muscles like the pec and the pec minor and we kind of lift the
chest up there's a very common pattern of respiration and i think it's that lifting of
the chest that is what's bringing the rib cage up and when that happens the body is a little bit out
of balance meaning your center of mass shifts forward and the body is a little bit out of balance, meaning your center of
mass shifts forward.
And the body senses that.
And in an effort to prevent you from falling forward, it's basically tightening those
erector spinae muscles.
It's pulling you into balance again.
But in doing so, it's creating this downstream problem in the hamstrings, which is they're
locking. And if there's another thing I've become really hamstrings, which is they're locking.
And if there's another thing I've become really obsessed with, it's hamstring control,
which is different from hamstring strength.
A lot of people, myself included, can have very strong hamstrings.
I used to have incredibly strong hamstrings if you put me on a machine and made me do
something in isolation, but I could never recruit them.
A simple exercise to demonstrate this, which Beth Lewis had me do
for the first time, maybe two and a half or three years ago, was laying on your back with your knees
up and your feet down. So you're sort of in a back position, knees up, feet on the surface of
the ground. And without letting your back tilt into a huge dome underneath it. So while keeping your lower back flat, can you with one leg pull
very, very hard back to your butt and feel your hamstring tense? So that is a very specific
manner of recruiting hamstring strength. And believe it or not, I couldn't do that
while keeping my back down. I would arch like a cat if I tried to do that.
There were many more of these types of exercises, but it was through this type of very deliberate starting on my back and then learning to do hamstring recruitment while standing
and while feeling pressure in my feet that really allowed me to get back to deadlifting
with a feeling of safety that I'd never really experienced because
I used to deadlift so heavy when I was young and basically got away with using my back to deadlift,
which is obviously not what you want to do. And then I just started having nagging injuries as
I got older. So by the time I was in my mid forties, I'm deadlifting and it's like,
oh, my SI joint would bug me. And after I'd finished,
my back would just feel tight. Age sort of exposes your deficiencies. And eventually
everybody's going to sort of pay a price for this. Some people do these things naturally
better than others. So I think there are some people who can kind of go their entire life
lifting heavy weights without having to pay much attention to this stuff. But you know,
I certainly wasn't one of them. Does that type of training that you're describing, that progression,
kind of starting back from the foundation or the fundamentals, does that have a particular name?
There are a couple different schools of thought that have been implemented into this training,
one of them being dynamic neuromuscular stabilization or DNS, which is heavily
focused on this ability to find the breath and generate this concentric
abdominal pressure. So creating a cylinder inside the abdomen, as opposed to like an upside down
triangle where you have some pressure up here, but none down here. And then another school of
thought that's been heavily influential here has been something called postural restoration
institute or PRI. That's really the one that has
focused on this idea of how do you correct what from the side looks like this, right? You know,
sort of pelvis down, ribs up, and how do you fix that position? And again, it's hard because it
requires fixing everything from the feet to the neck. How much of a contributor, if at all, do you think
extended sitting is to that configuration with the kind of flared ribs up and anterior pelvic tilt,
if any? I think it probably is. And probably for a couple of reasons, you have to sort of think
about it as the positive and the negative, right? So one drawback of sitting is that you're not active. It's simply the removal of active time that is a
problem. And I think the other problem with sitting is it is simply harder to generate
intra-abdominal pressure and it's easier to just rely on these accessory movements of respiration
to lift up. So I think I've said this once before,
if I could be czar for a day, I'd go back to kids when they're in school and have them in
standing desks or squatting. Those would be your two positions, right? So you either,
you're kind of squatting to do work or you're standing to do work, but you're not sitting
in the types of chairs that we sit in. I think I have an idea for a complimentary short-form podcast for you, which is just
called Czar for a Day. Five-minute commandments from Czar Atiyah.
Yep. And more barefoot time. With my first two kids, I wasn't so aware of this when they were
young. And now with my youngest, who's almost
four, I study this guy like he's the master. His movement patterns are simply unbelievable,
which of course all four-year-olds should be. I just never noticed it before. But the manner in
which he moves and lifts himself and reaches for things and sits around, it's incredible. It is such a spectacle to behold.
If you spend more time watching your children, and that's, you know, DNS is modeled on exactly
that, right? DNS basically says, it grew out of something called the Prague School in Czechoslovakia,
which was originally looking at ways to take children with cerebral palsy and teach them how to move
again by realizing that what cp had robbed them of was a lot of the developmental movement patterns
that occur in the first two years of life and once they started to realize you could actually take
these kids and retrain their neurologic system to do things in a more functional way that you could actually do
this as a form of rehab and then ultimately a form of prehab which is sort of how i like to
think of it now i've seen i don't know how much of this is public but incredible results from a
trainer also world record holder or former world record holder in Olympic weightlifting, Jersey Gregorek, working with a number of clients or patients with cerebral palsy using very
incremental movement rehabilitation and training. I mean, the before and after differences are
staggering. I mean, I speak to probably my ignorance of cerebral palsy, but just never was
even within my conceptual schema that that would be possible. It's very exciting to see. So speaking
of exciting. Oh, so the other thing on exercise to get back to your question about the metabolic
stuff is, you know, about three years ago, I was becoming more and more interested in this idea of
zone two training, which has a very technical definition. And then we can explain proxies for
it. But the definition of zone two is the highest level of output you can produce while keeping
lactate below two millimole. So lactate is a byproduct of anaerobic metabolism. So when
we're sitting here at rest, our lactate level is probably one. If we're metabolically healthy,
there are some people who sit around at rest higher than two. If anybody's done lactate
testing knows as you start exerting yourself more and more, your lactate will rise and peak levels
in highly trained individuals can reach above 20 millimole.
And that's accompanied by remarkable discomfort, actually. I've always done lactate training when
I was being an athlete, which I haven't been in forever, but I was never focused on this aspect
of it. I was always focused on something called lactate threshold and peak lactate. So peak
lactate for me was kind of a marker of just how much pain I could endure. And lactate. Peak lactate for me was a marker of just how much pain I could endure,
and lactate threshold was a marker of the highest amount of output I could produce
for relatively short races. Short for me would be half an hour or something like that. Knowing my
lactate threshold was important for that stuff. This zone two stuff is way below that. Zone two
is by definition your all-day pace. It's basically at a lactate level of two,
you should be able to go all day. That's the level at which you do not net accumulate. So
you're producing, but you're not accumulating. And so it's the rate at which clearance equals
production and you stay at that level of two. Just a very quick note to say that we really nerded out on zone two training with peter we
got deep into the rabbit hole it got very very dense also actionable but i moved that section
to the end of the episode so if you want to check that out later just continue listening now back to
the show you mentioned fat utilization or the ability to use fat as a substrate are there things and
specifically what's coming to my mind such as fasting or intermittent ketosis that help you
to use fat in such a way that it transfers to zone two training? Is there any crossover, I suppose?
Yeah. Well, there's no question that ketosis by its very definition is a nutritional state that
forces your body to utilize fat. And depending on how much you're intaking, some of that fat
could be endogenous. So again, exogenous is the fat that you put in your body. So what fat you eat is exogenous.
The fat stores that we have are endogenous.
There's a bit of a, I think, just a misunderstanding around ketosis.
I think a lot of people assume it is automatically a weight loss diet or a fat loss diet.
But of course, that's not necessarily true.
It's only a fat loss diet if you use your endogenous fat stores.
Also turns out a pound of fat has a lot
of calories yeah so you know i could gain weight on a ketogenic diet if i ate enough the advantage
of ketogenic diets for most people is that they're quite satiating and you don't want to
eat endless amounts uh in the way that if you went on the all dorito diet which i've also pioneered
i've got experience with the all dorito diet and uh turns out you can eat a lot uh the all Dorito diet, which I've also pioneered, I've got experience with the all Dorito diet. And, uh, it turns out you can eat a lot. Uh, the all licorice. I used to work
at a video store when I was in high school called movies and munchies. And you know, it was owned by
my friends, the video store plus dispensary. Yeah. And they just didn't care how much I ate. And I would literally eat
the pound of Twizzlers. They came in that pound, maybe a pound and a half. It was like the biggest
bag of Twizzlers. You could take out a mugger with this bag of Twizzlers. Yeah, yeah, yeah,
exactly. It's a weapon. And if any reasonable group of four people went to a movie, they'd
have a hard time finishing one. But I would easily throw that down plus the really big bags of Doritos, plus a really big bag of popcorn, plus God knows what else.
That was routine for the night. Just disgusting. Easily four or 5,000 calories of junk food,
three nights a week was my staple. So if we look at the opposite of that fasting has you have you changed your mind
or had any insights since we last spoke or come to any different conclusions related to
fasting because you've done a lot of fasting i mean you have a lot of experience doing
fasts of many different lengths including i don't know what the longest fast is that you've done
probably 10 days 10 days yeah yeah i think that one thing that I absolutely learned through fasting is the enormous importance
of strength training throughout a fast.
It's very easy.
You're going to lose muscle mass when you fast.
You have to accept that.
So the question is, how do you minimize that damage?
How do you lose as little muscle mass as possible?
And strength training daily during a fast has become an important part
of that. But when you look at time-restricted feeding, people call it intermittent fasting,
although I don't like that term very much. I think time-restricted makes more sense when you're just
talking about 16 or 18 hours. I'm really starting to see a lot of people who do that excessively
and who aren't necessarily training correctly, they lose weight,
but they're losing muscle more than they would want to see. And we just had a patient who we did
a DEXA scan on last week, and it was probably the first one we've done in 18 months on him.
And in that 18-month period, his body weight had not changed. Maybe he was a bit lighter, actually. He might have lost four pounds, but his body fat was so high, I almost fell off my chair. He doesn't look
chubby. It speaks to how much muscle he's lost. His body fat went from about 18% to 30%.
Yikes.
It's just a totally unacceptable amount of fat for someone
his age. And his visceral fat went up, which I actually care more about than body fat. We can
talk about that later, but his visceral fat also went up. So, you know, this is a guy who has
religiously been doing his time-restricted feeding every day, but he doesn't really lift weights.
He walks and does some yoga and stuff like that, but he's not doing strength training. So I think
in a person like that, there's a real downside to too much time-restricted feeding. And even for myself,
in the last four or five months, I did a DEXA back in January and I hadn't done one in years.
And from January to the last period that I had done a DEXA, my body weight was almost identical. Maybe I was two pounds lighter this
year versus the last time, but my body fat was up. I think I went from 10 to 16% body fat.
And again, you could say, well, 16 is not the end of the world, but that was a significant
loss of muscle and gain of fat. I did wonder if that was just too much because I always exercise
in the morning, but then don't eat
to exercise and then not provide yourself especially with when you're strength training
to provide yourself with any amino acids every single day to undergo muscle protein synthesis
i think it's a little bit risky so i've been looking at other strategies around that so for
example front loading the meal question and then we'll come back to front loading meals during that
period of time were you doing and i just i may be misremembering, but one three-day fast a month or one week between, it's also doing lots of time restricted.
And honestly, I think the daily time restricted was a bit more the issue. I think the three-day fast a month with a lot of lifting, I didn't sense I lost a lot of muscle during that period of time.
But I think every day, exercising in the morning, not putting calories in until later in the day,
it has to be taken in the context of an individual. So if you're someone who's a hundred pounds overweight or you have
diabetes, it's a totally worthwhile trade-off to lose muscle mass because you're losing more fat
mass along the way. So you are going to technically get leaner with that approach. But when you take
a relatively healthy and lean individual, one has to be a little bit careful and look for alternative ways to sort of get the benefits of that fast. So you were saying
something about front-loading meals? Yeah. So I just find nowadays, although probably not tonight,
I'm going to eat- Almost certainly not tonight.
I'm going to eat a little bit more early in the day and a little less late in the day.
So I'm going to- There may or may not be some mezcal involved.
There will be.
So we won't take either of our Oura ring data as standard for this evening.
I totally got caught up in my own fantasy narrative.
Fantasy's about mezcal.
So front-loading meals, can you just walk back and explain?
In an ideal world, I think that the best way to do time-restricted eating would be to eat a big breakfast.
So it would be to wake up, exercise, eat a huge breakfast.
By huge, I don't mean gluttonous, but I mean that's your biggest meal of the day.
I'd say, I don't know, let's just put some numbers to it.
You wake up at 6, you work out from 7 to 8.30.
At 9 o'clock, you're eating your largest meal.
You eat another meal at one o'clock that is modest
and you don't eat again.
That would be a great way to do 16 hours
of not eating a day.
That's problematic for two reasons.
The first is it's socially problematic.
It's really easy to not have breakfast
because very few people eat breakfast with other people,
but dinner is our social meal.
And for obvious reasons, it just poses a difficulty to be the guy who never eats dinner.
Just as a side note, I've been at multiple dinners now, quite a few actually, where you've
been fasting and we've all been sitting drinking wine and you just pass the cheesecake at the
end and you take a big whiff
and then continue moving it along it's entertaining but it is pretty antisocial yeah to be that guy
to be that guy yeah drinking the soda water um and then the other thing is i think for many people
it is hard to go to bed hungry and truthfullyfully, in longer fasts, it gets easier because if you're
fasting for seven days, by the time you hit that fifth day, a lot of your hunger has sort of
dissipated. But 16 hours of not eating can generally pose some hunger. And for some reason,
I just think psychologically in the evening, we're a little less busy. So it's even more noticeable.
Whereas if you're doing the traditional
way that people think about not eating for 16 hours, it's pretty easy to wrap yourself up and
work in the morning, skip breakfast and kind of delay your lunch a little bit. So I don't know
that I have a great answer for that other than I think people should be a little cautious and not
just apply the same hammer to every nail and kind of think about their own physiology a little bit and rely
on these technologies like dexa to make sure which again is so so readily available relatively
inexpensive and provides both good information about body composition and also this thing of
visceral fat we'll come to the visceral fat uh in just a second uh on the DEXA note, about, I don't know, a year and a half or two years ago,
I recall a conversation with a DEXA technician who said to me, over the last 12 months,
I've seen many cases of people coming in who are newly avowed intermittent fasters
who have had their body composition flip, basically. I mean,
not necessarily flip, but they've had massive jumps in the percentage body fat. And I put that
on social as a note, not to say that all people who do time-restricted feeding experience this.
And it was hilarious and also frustrating to see how many religious zealots there are
around intermittent fasting who were just like bite thy tongue you know but you said that
according to this tech that they got better intermittent fasting or worse they got worse
they got worse it met with what i'm describing exactly It's exactly compatible with what you're saying.
But there was a lot of resistance to the idea that that would even be possible, which I found really interesting.
More social commentary than anything else.
I think it just speaks to sort of why I don't like talking about nutrition very much because it does lend itself to politics, not literally, but it's sort of the politics,
religion, ethos, which is whatever you're eating is obviously the only thing. And I guess I just encourage people to be much more attuned to all of the tools, right? So caloric restriction,
dietary restriction, time restriction, right? You've probably heard me go on and on about my
framework, the three levers, always pull one, sometimes pull two, occasionally pull three, never pull none. So time restriction,
what we're talking about, restricting when you eat, but otherwise not restricting how much or
what. Dietary restriction is restricting some of the content in what you eat. So not eating carbs,
not eating wheat, not eating wheat,
not eating meat, not eating Doritos, right? Not eating sugar. Those are all forms of dietary restriction. And then caloric restriction is restricting the amount. And so if you are never
pulling one of those levers, which means you're eating anything you want, anytime, how much,
whatever, that's called the standard American diet. Sad. Yeah, the sad. And we've been running a very good natural experiment on that for 50 years,
and the data are in. So it turns out that less than 20% of the population, probably less than
10% of the population is genetically robust enough to tolerate the sad. So that's a great piece of data. There are people out there who can eat KFC
and Doritos and pizza anytime they want, and they're generally okay, to a first-order
approximation. I would add that we don't really know the answer to this question because we don't
have super granular data at the population level. But notwithstanding that, at least at the surface
level, it appears that 10% of the population are largely immune to the SAD. But notwithstanding that, at least at the surface level, it appears that 10%
of the population are largely immune to the SAD. But for the rest of the 90% of us schmucks,
which I'm certainly in that camp, the SAD is lethal. And so you've got to come up with a way
to escape the gravitational pull of the SAD. And that's why I think having these three levers at
your disposal is the key. And yeah, I think that what happens is people get so into the camp of their lever, like
it's all time restriction or it's all dietary restriction.
Not too many people are in the all calorie restriction group.
There's a whole calorie restriction society, so there certainly are people that are in
that camp, but it's usually the first two camps that have the most zealots.
Levers. I was waiting for the Canadian to come out. I love those levers.
Sorry. I'm sorry. I'm so sorry. Process. Process.
Process. I also think I said bite thy tongue. I don't practice my older English much. I think
it's thine tongue, but I'm sure the internet will correct me.
Just a quick thanks to one of our sponsors and we'll be right back to the show.
This episode is brought to you by Athletic Greens. I get asked all the time what I would
take if I could only take one supplement. The answer is invariably Athletic Greens.
I view it as all-in-one nutritional insurance.
I recommended it, in fact, in the 4-Hour Body. This is more than 10 years ago,
and I did not get paid to do so. With approximately 75 vitamins, minerals,
and whole food sourced ingredients, you'd be very hard-pressed to find a more nutrient-dense
and comprehensive formula on the market. It has multivitamins, multimineral greens complex,
probiotics and prebiotics for gut
health, an immunity formula, digestive enzymes, adaptogens, and much more. I usually take it once
or twice a day just to make sure I've covered my bases if I miss anything I'm not aware of.
Of course, I focus on nutrient-dense meals to begin with. That's the basis.
But Athletic Greens makes it easy to get a lot of nutrition when whole foods aren't readily available. From travel packets, I always have them in my bag when I'm zipping
around. Right now, Athletic Greens is giving my audience a special offer on top of their
all-in-one formula, which is a free vitamin D supplement and five free travel packs with your
first subscription purchase. Many of us are deficient in vitamin D. I found that true for myself,
which is usually produced in our bodies from sun exposure.
So adding a vitamin D supplement to your daily routine
is a great option for additional immune support.
Support your immunity, gut health, and energy
by visiting athleticgreens.com slash Tim.
You'll receive up to a year's supply of vitamin D
and five free travel packs with your subscription.
Again, that's athleticgreens.com slash Tim.
Quick tactical question, and then I want to ask you about any research or studies that have been
interesting to you that have come out since we last spoke. Is it effective or have you tested using small amounts of branched-chain amino acids
to mitigate the muscle loss during what we would otherwise consider fasting? And does that also,
if it has any effect, lessen the benefits of the fast? It depends on what you're doing the fast
for. I think if you're doing the fast for weight loss, then the answer is absolutely knock yourself out with branched chain amino acids
during strength training. Because from a caloric perspective, they represent such a pinch.
Yeah, yeah, yeah. Like even if you were to double up on, you know, my favorite BCAAs,
which are BioSteel, you know, you're, what are you going to get in there? 40 calories in two servings,
so not an issue. If you're doing the intermittent fasting, would call it the hope of achieving
some amount of the early signatures of autophagy, then I would say that it probably
is counterproductive because the amino acids that you use in exercise are exactly the
ones that are the most potent stimulators of mTOR. And the whole purpose of fasting,
at least in the short term, is to give mTOR a rest. It's to take away that which it senses.
And it is the most potent sensor of leucine, which is the most important branch chain amino acid yeah so if i could dumb
that down for myself if you are interested in the longevity benefits of fasting aside from just
getting too healthy body composition you should not take the branch chain amino acids i mean i
can't say anything with certainty but it seems seems counterproductive. Yeah. Yeah. Got it. All right. Studies. Any papers or studies that
you found interesting? Oh my God. So many. There's a lot. If you had to cherry pick a few.
Well, look, I think the recent New England Journal paper that you and I have talked about
is very interesting comparing Lexapro to psilocybin. I wrote about it recently and my little diatribe basically said, I think the
paper was in some ways misinterpreted. It was positioned as a negative trial,
though I saw it as anything but a negative trial. I mean, just for background.
Could we zoom out just for a second and give people an overview of the objective or the
hypothesis of the study? Yeah, the question that was being
tested was, is an intermittent dose of pure synthetic psilocybin more effective, I think is
the way the question was posed, than the top-tier SSRI for patients with depression? Yeah. So Lexapro
is a relatively new SSRI, very well tolerated. Is it teleprim?
Yeah.
It does have sexual side effects.
That's its most common side effect.
That's true of other SSRIs as well.
Absolutely, yeah.
SSRIs are known for having sexual side effects.
Some of them also come with incredible amounts of somnolence, incredible amounts of weight gain.
Somnolence, sleepiness.
Sleepiness, yeah.
Lexapro seems to be relatively
free of that for most people, which is why it's kind of more of a go-to drug. Comes in two doses,
10 and 20 milligrams. Generally, most people need 20 if they're going to go to it, but you usually
start people at 10, go to 20. This is a daily administration. It's a daily drug, yep. The
participants are divided into two groups. One group is given
Lexapro. Let me think. I believe that they all started out at 10 milligrams for three weeks and
then were increased to 20 milligrams for three weeks, or maybe it was four plus four. I can't
remember. It was a relatively short study. In the psilocybin group, the participants were given,
oh, by the way, it's an aside. They were also given one milligram of psilocybin,
which is an important point I should make.
And if that word is unfamiliar to folks, psilocybin is a molecule found in psilocybe mushrooms, also known as magic mushrooms.
These are mushrooms that impart psychedelic effects at a sufficient dose.
We'll come to talk about that dose. So the subjects were all recruited knowing that they
would get psilocybin no matter what, because that was an important recruiting tool. People wanted to
be in a study where they were going to get the psilocybin. That has to be taken into account
from the standpoint of patient selection. So every trial has to be thoughtful about what type of
people it's selecting and are they representative of the population you're going to want to extrapolate your results to. So I flag this
to make the point that when you have a patient population that says, I really, really want to
get psilocybin and you say, okay, well, you're not going to get necessarily the full dose. There's
only a 50-50 chance you're going to get the full dose, but you're going to get some. So you're
either going to get one milligram or 25 milligrams. And we'll put in context what those
doses mean in a second. And just to bracket one thing, what makes this study and paper
worthy of discussion is that it is a head-to-head comparison with lots of nuance, of course,
of psilocybin with, I think, two or three sessions total in the intervention arm versus Lexapro,
very common SSRI for major depressive disorder. Please continue.
Yeah. So to your point, the group that was in the true psilocybin group received,
I think it's just two doses spaced out three weeks apart of 25 milligrams of psilocybin,
which depending on the variant of mushroom.
So when you dry a mushroom out, its yield of psilocybin, pure psilocybin can be as low.
I mean, I went and reviewed all the lit on this can be as low as 1.7% can be as high
by weight can be as high as even four or 5%. So incredible variability.
Yeah. So the 25 milligrams was clearly a hallucinogenic dose. So probably in the four
to five gram of mushroom dose. So they used a number of, well, there's one other point I should
explain about research. Generally when research is done in a credible fashion, you have to call your shot before you do the study.
It's like pointing the center field.
That's right. You have to be able to not just say, I'm going to hit a home run,
I'm going to hit a home run over that wall. And that's called your primary objective.
So one of the things that is important to understand when you're evaluating research
is, was it pre-registered? So when the study-
Right. Did they call their shot by naming their primary outcome?
That's right. And so in the United States, anything that's funded by NIH, for example,
has to be pre-registered on clinicaltrials.gov. So I would encourage anybody to go to
clinicaltrials.gov and just start perusing. And what you'll see there is a list of all of these ongoing
studies. They'll say, you know, started here and it's a template. So it always looks the same. And
it's very easy to navigate these things. You know, here are the investigators. Here's the hypothesis.
Here's the experimental design. Here's the inclusion criteria, the exclusion criteria.
Here are the primary, here is the primary outcome. Here are the secondary outcomes. And it shows you
all of that stuff. So you have to pre-register this. You have to state what you're doing. If you don't do that,
it becomes very difficult to publish your work in anything prestigious. This of course was published
in the hands down most prestigious medical journal in the world, the New England Journal of Medicine.
So they pre-registered around one type of survey, one type of depressive survey, because unlike,
say, giving people drug to treat cholesterol,
where you have an objective metric, you can say, well, did it lower ApoB or LDL-C or something
like that? Here, you're relying on subjective outcomes. Because in such a short study,
you're clearly not going to be able to follow people for, wait, was there less depression in
this group? Or was there less suicide in this group? Was there less suicide in this group or something like a hard outcome? Did people have fewer absent days from work or
something like that? And it's been a while since I wrote this. The primary survey that they used,
I believe, had nine categories or maybe it was 12. And the difference between the groups,
the Lexapro group and the psilocybin group, was not statistically significant.
So both groups achieved an improvement in their depressive scores.
Yeah. I think it was six and four points, respectively.
Correct. I think it was a nine-point scale.
Something like that.
Yes.
But you pointed out something very important. And I guess we should just step back for a second.
So the upshot, and then let's come back to these questions but the upshot summary of the
study was what there was no difference between psilocybin and this drug it was positioned as a
negative study got it meaning it i mean i don't want to say failed because it's just not really
how science works but that the intervention did not meaning, psilocybin in this case, was not superior to S-telogram.
That's right.
All right. So this is a topic that is endlessly interesting to me, what we're getting into,
which is study design and really digging into the nuance and how beneficial it is to know how to
read a study. And I mean, this will seem like a friendly plug, but I highly recommend
people read a series of articles that you published and they are called, what is it?
Studying the studies or studying studies, studying studies to increase your scientific literacy,
because we're going to get into some of the weeds. And I think it'll be, I hope it'll be
interesting to people. And the other thing we're doing, if I can plug something and I don't know
when we'll have this out yet, but we're creating a course where about a year ago, we started recording
our monthly journal club.
So every month inside our practice, we do journal club, which is just like old school
journal club for anybody who's been in a lab.
So one person will present a paper.
It usually takes an hour to an hour and a half. And we get into a complete
dissection of the paper. And we do it in a really kind of methodical way. And the topics vary
greatly. So I highly recommend everyone do this, honestly, witnessing the complete mayhem and
confusion over the last year with respect to anything science related. Certainly the most
obvious of which being anything COVID or vaccine related has made it so clear to me that this is really, I mean,
it's hard for me to think of something that is higher priority.
Yeah. And we just decided to do this. I mean, we've been doing Journal Club inside our practice
for years, but it occurred to me a year ago, why aren't we recording this to later package and put
out there? Because nobody comes out of the womb knowing how to read science. We just have to
accept the fact. It's completely learned. It is a totally non-innate thing. Evolution had zero
desire to teach us this skill, so you have to learn it. And some of us were really lucky to be
in labs where people were really good mentors and they
they beat into you how to do this and again the topics that we explore are you know the latest on
semaglutide which we'll talk about today i think the role of testosterone replacement therapy in
men with type 2 diabetes a huge paper that came out recently this topic so it doesn't matter what
the subject matter is the process of thinking
is actually quite the process of thinking dissecting and skeptically but not necessarily
cynically looking at the purported outcomes i think is is really important so coming back to
this paper super prestigious journal study comes out psilocybin versus lexapro
negative study or negative outcome rather then we have this questionnaire let's just call it
that is determining the results and the differences come back as statistically
insignificant however right as you pointed out when you wrote about this, that doesn't necessarily mean clinically insignificant.
Nor does it mean that it wasn't. So let's go back and explain what statistical significance is as
well. Because now there's three points. You reminded me of something else that I think is
worth stating. How is statistical significance determined? And what does it mean? We hear this
term all the time. Statistical significance is basically asking a question, what is the probability that the
difference that's observed between these groups is by chance? To answer that question, you have
to know a priori how big an effect size you would expect to see between these two groups.
A priori meaning beforehand you need to know what magnitude of difference you expect to see between
the two groups. That's right. And that's really important because that determines what's called
the power of your study. Part of the importance of guessing correctly, maybe that's not guessing,
but determining or speculating or guessing correctly the magnitude of difference,
like the difference in effect sizes, because that also will determine how many subjects you need to recruit. That's right. So there's something
called a power table, which I think we include in one of the studying studies articles, which I
remember when I got to the lab was one of the first things my PI, principal investigator,
showed me. He said, this is going to be one of the most important tables you'll ever pay attention to
when you're doing research it's a complicated table to look at but on the horizontal axis
it has effect size of treatment a on the vertical axis it has difference between treatment a and
treatment b so this will be like 10 15 15%, 20%. And then here it would be
like 5, 10, 15, 20. So for example, treatment A would yield, if you predict it's going to be a
30% effect size versus a 40% effect size, you go to 30 and 10. Does that make sense? You're the
baseline plus the Delta. And then within each square, you typically have two options at either
80 or 90% power. Obviously 90% power means an even higher standard and it requires more sample,
it has a greater sample size. So it's very common in research to underestimate or overestimate your effect size and if you overestimate the effect size
you can underpower a study and i think there's actually a pretty sizable chance that that
happened here yeah because the power analysis suggested they were looking for a four point
difference on this scale it It came back with two.
It came back with a little over two. A little over two. Yeah. So it's not surprising that it
came back not statistically significant because they had engineered the number of participants
to only be statistically significant if there is a difference of four points or greater.
So on the one hand, you would say, well, that's really impressive. That was a very high bar.
My question is, was it too high a bar? Is four points necessary when you're really trying to do
a study against the gold standard? It would be one thing if you were doing a study against a placebo, where you do want to set a very, very high bar.
But this is akin to almost like a phase three drug trial, where you're trying to compare a new drug to an existing blockbuster gold standard drug,
and simply being non-inferior to it, and maybe even potentially better on some of the secondary metrics as this one was,
could be more than enough to advance clinical utilization and promulgate further studies so that was one of
my first concerns with this study was i don't think it was powered correctly because i i do
wonder if four was too high an expectation against this treatment of course other issues are was this
study long enough this was a relatively short study and it could have gone the other way. It might be that after
a year it flipped and Lexapro was hands down the winner and psilocybin's effect waned. We don't
know, but again, that's another thing to be concerned with. And then the point that you
brought up, which is a subset of what we were just talking about is look, maybe a two and a
half point increase is clinically really relevant. And the other point here is,
And I definitely want you to give, if you remember, and it can be rough, but some of the examples of
the questions. That's right. And that's, that's the final point here is not all questions are
created equal. So some of the questions on that scale are like, are there times when you don't feel good about yourself versus there are
days I can't get out of bed? Those are not the same question to me. Like those are very different
questions. A person who says, yeah, like honestly more than 50% of the time I don't feel good about
myself. Clearly that's a problem and clearly that's something you want to address, but that's,
that person is probably a lot more functional than the person who says I can't get out of bed. Yeah. Or I think that, you know, the, uh, another
two examples to compare would be one about suicidal thought as well. Right. Right. And,
or I sleep 10 or fewer hours per day or 12 or more hours per day. And that might account for,
say a two point difference on an individual
questionnaire.
But then another question,
which was something like,
I feel badly about myself most of the time versus,
or on a daily basis versus say less than half the time or something along
those lines.
Then as you mentioned questions that could include suicidal ideation.
So not all points are created equal.
Right. Another thing that I wondered, because I have in part helped fund research at Imperial
College, where this came out of, and a bunch of other places. And in conversations with a number
of different neuroscientists, they said, well, these are people who are very experienced with
designing studies and being published. They said, well, these are people who are very experienced with designing studies and
being published. They said, well, you know, there are times when you have to choose between
the primary outcome measure you think the establishment, so to speak, is going to most
respect or the primary outcome measure that you think is going to move the most.
And this could be a case, and I'm not speaking for Robin or anyone else involved with this study, but this could be an example of picking what the establishment would have wanted to see and then having the secondary outcome measures move in some very interesting ways that maybe in retrospect could have or should have been the primary outcome measure.
Correct. If you had more confidence in those to begin with. Do you know what the budget was for this study?
For this study, I don't, but I'm glad you mentioned budget simply because I think this
underscores how important, at least in the US, because I'm involved with Hopkins and UCSF and a number of other places,
how important it is to try to open up state and federal funding for this type of research
from NIMH, NIH, et cetera, because right now it's easier for someone to say, well, that was stupid.
Why didn't they just have 50 people in each arm? And the answer is it costs a lot of fucking money and it's hard
to raise money in some cases. So, I mean, that was just the point I want to make, but I don't
know what the budget for this was. Yeah. I mean, look, I think net net, this study must be viewed
as a very positive finding because the side effect profile was obviously higher in Lexapro. So again,
people taking Lexapro are far more likely to complain of if their males erectile dysfunction, sexual malfunction, reduced libido, things like that. How we wouldn't want to explore this to the nth degree, I don't understand. And of course, there's other things I'd want to explore like microdosing, right? These were macrodoses. So these are people taking a full hallucinogenic dose every three weeks, I believe.
And that's not necessarily an easy thing to do either. So we, you know, I'd want to understand
what that's like versus what would taking a couple of milligrams per day, which would be well below
the threshold of perception or three times a week or something. You know, you hear a lot of anecdotal
talk about those things being beneficial to people. I like to see that studied and in some ways that would be an easier thing to study because that's the other limitation
of this study which must be noted which is technically it was not a blinded study yeah
it was a randomized study but it wasn't a blinded study there was no confusion about which group you
were in this is one of the biggest challenges i think there are ways to solve for it that I find pretty compelling from a scientific standpoint,
but it's very hard to blind when you're using hallucinogenic,
a much less sort of mystical experience level dosing of a psychedelic.
And it raises, as you noted, given the frequency of administration.
So you have, say, two sessions with psilocybin at
clearly psychedelic doses these would be i would say in most people sufficient to produce
some type of what you might call mystical experience and there are questionnaires that
johns hopkins has developed roland griffithiths and Matt Johnson and that team to measure mystical experience, ego dissolution, sense of unity, etc.
But when you look at the results, and we assume for the time being, even though I think people
should look really closely at the appendices and the secondary outcome measures, let's say that
they're breakeven. All right, this is a tie but on one hand as you said
you have more side effects you have daily administration and then on the other hand
you have administration every three weeks and i think that were they to and they may still plan
on doing follow-ups in other university studies there's quite a bit of durability that's seen
with this type of administration of psilocybin, even out to six, 12 months. It raises some really interesting
questions, the most obvious of which is, how does this work? Because if the SSRIs are on some level,
I don't want to say suppressing symptoms, maybe masking tendencies, I don't know the right way to phrase it, but it is a maintenance
drug. It's an ongoing administration versus highly intermittent. By what mechanism
are these changes taking place? Is it just flooding the brain with a compound that has
a biochemical effect, or does it relate more to changing the content and narrative and sort of
what work can be done in those sessions themselves?
Raises a lot of interesting questions.
Yeah, and I think with MDMA, I think the answer is probably a bit more clear.
Prior to MDMA's resurgence and serious treatment for PTSD, antidepressants were the mainstay of therapy for this.
And I think it was exactly what you said. I mean, antidepressants for PTSD were a masking agent that had some efficacy, but not tremendous efficacy. the chemical changes in the brain as a result of the administration of the molecule and far more
about the state of mind that it puts the individual in for the type of therapy that they need to do to
go back and rectify and come to grips with the traumatic event. And I think you're right. I think
it's less clear here, but it also doesn't have to be one or the other. It's certainly possible it
could be both. And there's been, for those for those people interested in reading more and i can link to these in the
show notes for this episode there has been some great new york times coverage of the phase three
trials related to mdma assisted psychotherapy includes stories from subjects it's a very
compelling read the results are really pretty staggering and raise a lot of
exciting questions for me about the future of treating mental illness or psychiatric disorders.
And I also want to give just a shout out to Rick Perry in Texas, who has been recently very public
about exploring psychedelic compounds as possible treatments for things like ptsd
among veteran populations and other subpopulations that i think is a very it's very courageous and
very justifiable stance to take so i was very excited to see that especially in the great
republic of texas in which we sit that right. Any other studies that come to mind?
Or you mentioned APOB.
I'm wondering if you have any thoughts on APOB that you'd like to share.
Yeah, certainly as it pertains to things where I'm evolving my thinking, I'm...
And what is APOB?
Yeah, it's probably worth explaining that before we do anything else.
Most people have heard of cholesterol and most people are used to seeing a blood test where you would see your total cholesterol,
LDL, HDL. If the lab is half decent, it would actually say LDL-C, HDL-C, non-HDL-C, VLDL-C.
What does all that mean? So that means LDL cholesterol or the cholesterol contained with
an LDL. HDL cholesterol is the cholesterol contained within LDL. HDL cholesterol
is the cholesterol contained within LDL. So why do all these things even exist? So every cell in
our body makes cholesterol. It's an essential molecule for life. So if you don't have cholesterol,
you're not going to live more than a few seconds. In fact, you'll die in utero if we're going to be
blunt. So every cell makes this thing. It makes up the cell membrane of every cell.
It's what allows membranes to have fluidity and have transporters sitting across them.
It's also the backbone for many of the hormones we make. Now, the problem is cholesterol is not
water soluble. So when you have something that's not water soluble, that needs to be transported
through the body, which this does, because as I i said not every cell makes enough of it to meet their own needs so there are net exporters and net
importers of cholesterol you have to have a system that can move it around but just like if you tried
to pour olive oil into a glass of water you would quickly realize they don't mix and similarly you
can't just move cholesterol through the bloodstream the
way you can move things like glucose, sodium, potassium, things that are water-soluble. So
glucose just travels through the bloodstream on its own, as does a ketone body, for example.
But triglycerides have to be bound. Things that are fat-soluble have to be bound.
So Mother Nature invented something called a lipoprotein, which is a
spherical thing that on the outside is water soluble. And on the inside houses, these water
insoluble or what we call hydrophobic things, namely cholesterol, ester, and triglycerides.
And these lipoproteins exist in two broad families, and the families are defined by the protein signature that wraps around them. So the two families are the ApoB family and the ApoA family. Technically, there's a subclass of the ApoBs. There's an ApoB100 and an ApoB 48. But for the most part, anybody that's talking about APOB is referring to APOB 100.
The APOB 48 is only something called the chylomicron. It is a very short-lived
lipoprotein that gets fat out of your gut. So let's put that guy aside for the moment,
unless anyone wants to come back and we'll do the advanced course on the weekend.
Okay. Advanced course for the midichlorians, you nerds out there. All right.
So your ApoB family consists of very low density lipoprotein or VLDL, intermediate density
lipoprotein or IDL, low density lipoprotein or LDL, and LP little a, who is the worst actor of the bunch, which is an LDL with another special
lipoprotein wrapped around him called an APOA or an apolipoprotein little a. Not APOA, I should be
really clear. It's apolipoprotein little a. You have to specify little a to not confuse it with
the APOA family. The APOA family is the lineage of the high density lipoproteins. Most people know that HDL good,
LDL bad, but that's a little overly simplistic. What we really mean to say is that HDLs do not
cause atherosclerosis, LDLs do. But it turns out LDLs aren't the only thing that cause atherosclerosis.
Anything with an ApoB on it causes atherosclerosis. And just for the listeners, atherosclerosis, meaning the buildup of plaque within the
cardiovascular system, how do you think about that? Stiffening or inflammation?
It's the inflammatory disease of arteries that ultimately results in plaque formation,
and in the worst case scenario, results in rupture of this plaque
that leads to an acute thrombosis or an acute occlusion. And if it occurs in the wrong spot,
that can be fatal, instantly fatal. Got it. So VLDLs stick around for long enough that if you
have too many of them, they are atherogenic. IDLs are not really a problem because they just don't
last that long. So the transit from VLDL to IDL and then IDL to LDL is so quick that the IDLs are not really a problem because they just don't last that long. So the transit
from VLDL to IDL and then IDL to LDL is so quick that the IDLs are kind of irrelevant.
LDLs, of course, are the majority of your ApoB concentration, unless you also have a lot of
insulin resistance where you might have high VLDLs, or if you have a genetic condition that predisposes
you to have too many of those. The IDLs, again, we don't really worry about those. The LDLs, or if you have a genetic condition that predisposes you to have too many of those, the IDLs, again, we don't really worry about those. The LDLs are the lion's share of your ApoB,
and about one in eight to one in 12 people also have a very genetically high level of LP little
A, and that also represents part of the ApoB concentration. So ApoB is a far superior
measurement to LDL-C when trying to predict cardiovascular risk. So it is hands
down the best biomarker we have for cardiovascular risk because it is the total concentration of all
particles capable of inducing atherosclerosis. Now, atherosclerosis is multifactorial, so lots
of things drive it. Inflammation plays an important role and metabolic
health plays a super important role, but we understand that lower ApoB is better. Where I
think the data are becoming more and more clear is how low you can push this thing without unwanted
effects and how much more benefits you can get. There's always a concern, I think, and understandably
so, that if you lower ApoB, you're lowering cholesterol. Because if you have fewer of the
particles that carry cholesterol, you have less cholesterol floating around the blood.
But what most people don't understand is that that's sort of like saying,
I'm going to reduce the number of cars traveling over this bridge, does that necessarily
mean you're reducing the number of cars in the city? Not necessarily. So most of the cholesterol
in your body is not in the lipoproteins rummaging around through your veins. Again, most of the
cholesterol is still sitting inherently in the cells itself so if you
took a person's total cholesterol and it was 200 milligrams per deciliter and you lowered it total
cholesterol by the way at this point i assume is straightforward to explain it's the sum of all the
cholesterol and all the lipoproteins so the vldl idl ldl lp little a and hdl if you bash all of
those particles and take out all the cholesterol
that's what your total cholesterol is if you took that number from 200 to 100 you would say god
that's a 50 reduction in your cholesterol no it's a 50 reduction in your serum cholesterol which
might be like a five to ten percent reduction in your total body cholesterol so that's one thing
to keep in mind the other thing to keep in mind is we are born with very, very low levels of cholesterol. So in a child, the ApoB concentration
is probably in the ballpark of 30, 20 to 30 milligrams per deciliter. By the time we're
adults, a level of 80 milligrams per deciliter would put you at the 20th percentile, meaning
80% of people would have
a higher number than 80. What's the upshot of this? The upshot of this is there's no upside
to having more ApoB. The upside is in having that number be lower and lower and lower.
But until recently, it wasn't clear how low you could drive it. And there was a type of drug that was developed about 17, 18 years ago,
but it became clinically available. I shouldn't say that actually, it's probably started development
in about 05. So it was called 16 years ago, hit the market in 2014 or 2015, a class of drug called
PCSK9 inhibitors. And they work in a manner that's distinct from all previous drugs that lower cholesterol.
They work by inhibiting a protein that degrades LDL receptors on the liver.
And by inhibiting this thing that degrades them, you get more of the LDL receptors on
the liver.
It pulls more of the ApoB-bearing particles out of circulation, mostly which are LDL particles,
but also some Lp little a particles. With these trials we
see people achieving levels of ApoB in the 10 to 30 range with no side effects, no consequences.
Furthermore these drugs were developed when populations of people were identified who
naturally had mutations in PCSK9 that rendered their PCSK9 ineffective. So this was
basically a drug that was designed to mimic a genetic mutation found in people who over the
course of their lives have no increased risk of any disease and simply have a decrease in their
risk of cardiovascular disease. In fact, the risk of cardiovascular disease is virtually non-existent.
Let me ask a silly question. How does one find people who have such a mutation to track them? Well, it started with the opposite.
So there's a condition called familial hypercholesterolemia, or FH for short, which are
people who have very high levels of cholesterol and very high levels of LDL cholesterol, and by extension, very high levels of
ApoB. And they're pretty easy to spot, but it's a definition that is based on phenotype, not
genotype. So it's genetic condition, but it's one phenotype, but 3,000 or more genotypes, meaning
there are thousands of different genetic mutations that lead to that. I think it was in the late
nineties. One of those genetic pathways was identified as a hyper-functioning PCSK9.
So a group in Toronto identified PCSK9 and realized that these people had a hyper-functioning
version of this protein and it was constantly degrading LDL receptors. And so they just couldn't clear
the ApoB out of their circulation. And that's why they had sky high LDL and total cholesterol.
When that population was identified, the question was asked, which is, is there a counterpart to
them? And it turns out to be really easy to identify them because they're the opposite.
These are people who don't take any medicine to lower their cholesterol, and they have
levels like infants.
And I remember actually reading that paper when it came out and being blown away and
actually thinking, there's no way they're going to be able to do this with a drug.
But it turned out it was actually pretty druggable.
It wasn't that hard to do.
And in many ways, it's a much cleaner drug than say a statin. Like statins,
which are, despite all the public mayhem around it and the religious polarizing debates around
statins, statins are really safe drugs. 10% of people have unwanted side effects and shouldn't
take them, but they're very well tolerated drugs. And in my mind, that's kind of a miracle when you
consider what they do, which is they inhibit cholesterol synthesis.
And when you think about how important cholesterol synthesis is, it's kind of amazing to me that that works without killing people. My hypothesis for this, by the way, is that statins occurred in
nature. So the first statins were really copying something that was found in nature called red
yeast rice. And as a general rule, I think things that came from nature tend to be a little safer, psilocybin, rapamycin, metformin, some of my other
favorite drugs. But the method by which the PCSK9 works is just elegant because it's really just
targeting one protein with an antibody that makes it harder for the LDL receptor to break down.
Are there any benefits to lowered or low ApoB outside of cardiac risk, lowering cardiac risk?
Yeah, there actually is.
Or I shouldn't say cardio, cardiovascular risk.
Yeah, yeah, yeah. And that's sort of, I mean, I think we've known for a while that it also
poses a benefit with respect to Alzheimer's
disease, for sure. And that's one of those things where I think one needs to be a little bit careful
about never confusing population data with individual data. And it's why I think population
data are fantastic, but every patient has to be completely assessed as an individual.
So the population-based data, for as long as we've had statins, we've known that lower ApoB or lower LDL-C means less risk of Alzheimer's disease.
And if you think about some of the paths by which people get Alzheimer's disease,
there's clearly a vascular path. So Alzheimer's disease is not a disease.
Just in the same way, cancer is not a disease singular. It's many diseases, not just tissue type, but even within tissue type,
you know, within breast cancer, for example, you have different receptor profiles, the same within
lung cancer. So, or even just the mutation can render two cancers, completely different animals.
And similarly, Alzheimer's disease is a collection of lots of diseases with a final common pathway,
but you can get there metabolically. You
can get there through a vascular path. You can get there through an inflammatory path.
There might even be an autoimmune path there. The vascular path is a big path in my opinion,
and therefore anything that improves microvascular health, which statins do,
should improve the risk of Alzheimer's disease. So there was something called the
Mendelian randomization that was published, I think like literally a week ago. And I'll explain
what a Mendelian randomization. Yeah. Yeah. So I guess I should explain what an MR is first. MR is
Mendelian randomization. Correct. Is a very elegant tool that allows us to try to infer cause when an experiment is not done.
This is a profound idea because when you just observe things without doing an experiment,
which by definition means randomly assigning treatments or assigning treatments to randomly
separated groups, which is the only way to eliminate all
bias. There are other biases that can creep in, which we could, I mean, which are actually
discussed in the studying, studying section. I won't go into like performance bias and other
things like that, but for much of the questions we're interested in, you can't do that. You have to rely on natural experiments. So what MR allows you to do is identify genes that are responsible for the traits at hand and not responsible for other traits and do basically a model of what does that genetic trait tell you when it's present or not present. So the idea is,
in an MR analysis, you're basically assuming that genes can occur randomly, which of course they can,
and you're then looking at what is the outcome from that. So for example, in the case of ApoB,
you would look at genes that are determining ApoB level. And there are many genes that play an important
role in understanding how high or low a person's ApoB is. And these genes are set, right? It's sort
of like you get the gene, you get, you know, you're not going to change the gene and it's not
subject to your behavior. Whereas so many other things like what you eat is a behavior that can
also impact your ApoB. It's how do you strip that
effect out, the healthy user bias, all of the things that are problematic when trying to infer
this. And the MR demonstrated quite clearly that lower ApoB is synonymous with improved all-cause
mortality, cardiovascular mortality, and even mortality associated with
diabetes and things like that. To me, the most interesting finding in there was the all-cause
mortality. On the one level, you could say, well, that's not surprising given that cardiovascular
mortality is the greatest cause of mortality in the developed world. So if you take a big
enough chunk out of that, you should improve all-cause mortality. But nevertheless, that study combined with a number of other very large cardiovascular trials, namely Fourier, Odyssey, Improve It, every trial has to have a cool name, just demonstrate this effect where lower is better.
The lower the LDL goes or the ApoB goes, the lower the risk goes. Let's jump to rapamycin since you mentioned it and you can give a very
quick idea on what rapamycin is. But since we last spoke, more bearish, more bullish. And why?
I'm a bull. Yeah. Dogecoin and Rappa? Diamond hands? All right. So what is rapamycin? By the way i mean i know i know what the diamond hands thing
is but what is it where did it come from like no idea yeah i have no idea where diamond hands
comes from okay i i was like did i miss that somewhere in my in my in your in your in your
econ classes yeah yeah no i don't think so okay so what rapamycin? So rapamycin is a drug that is a naturally occurring antifungal agent made by a bacteria
that was discovered on Easter Island back in the 1960s.
Otherwise known as Rapa Nui.
Right.
Rapa Nui is the correct name for Easter Island and the bacteria Streptomyces hydroscopicus,
which was discovered there
by a group of explorers, explorers is maybe the wrong word, but people doing sort of medical
prospecting, a group from Montreal, I believe, in 1966, they took a bunch of soil and dirt back
from Rapa Nui to the lab in Montreal, where it sort of sat there unattended to for about five
years. A chemist, a very astute chemist by
the name of Saren Segal. Great name. Yeah. He started mucking around. Related to Steven Segal?
No. And no ponytail, fortunately. So Saren did some really interesting chemistry,
isolated the compound, and noticed it had these really remarkable properties,
which was it was the most potent antifungal agent he had ever seen or the world had ever seen, frankly.
At the time, as his son Ajit tells the story, who I've gotten to know a little bit, he felt
he had basically come onto the biggest blockbuster cure for athlete's foot the world was ever
going to know.
And right about that time, the company he worked for closed its Montreal headquarters, actually laid many people off, ordered the destruction of all non-viable compounds and shipped him off to New Jersey. not follow orders and he instead stuck said rapamycin into a little mini freezer that he
and his family transported to their new home in new jersey they kept it in the freezer for many
years until ultimately another drug company purchased the company he worked for and the
new management said hey anybody working on anything interesting he said i'm working on
this thing interesting that i haven't looked at in a few years. And they said, bring it out.
Must have been an interesting lawyer conversation based on the not following orders. Continue,
yeah. So out came rapamycin, which he named. Mycin is typically the suffix, I guess, that we use,
or what's the second part of a word called? Suffix.
Suffix, yeah, for antimicrobial agents. And of course, rapa is a tribute to the rapa newi. Like azithromycin. Correct.
It quickly became clear that this had remarkable anti-proliferative properties. So it could stop
things from proliferating. So that was obviously a big part of- Not just fungi. Right, exactly.
And in particular, it was very effective at making a certain type of lymphocyte, which is a type of white blood cell, not proliferate. And it then basically went down the path. Eventually, Pfizer then bought Amaris, which was the company that bought his previous company, whose name I don't even remember at this point. up pursuing this and it was fda approved in 1999 for treatment of organ transplantation so patients
that have an organ transplanted have to be put on a really heavy regimen of drugs to suppress
a part of their immune system called the cellular immune system that will attack a foreign organ
that's what is that called host graft no no graft versus host is actually when the organ usually
it's in the case of lymphoma or leukemia,
when someone has a bone marrow transplant and the graft, what they've been transplanted,
attacks the host. I see. Yeah. This is really host versus graft, but we don't usually call it that.
Yeah. But traditional sort of rejection. Actually, I did a really cool podcast on the topic of organ
transplantation history with a guy named Chris Sonnenday.
And it's, I mean, I know this subject well, but having the discussion with Chris really opened my eyes to just what a beautiful story it is and what the big breakthroughs were with drug development.
And how, you know, at one point it was like all you could give people was prednisone and you couldn't save anybody.
And then you had other drugs like cyclosporine that were introduced, but then you get into this third generation of amazing drugs like rapamycin that took organ
preservation to a, to a higher level. Now you're not swapping kidneys.
How do you know? Well, at least not since the last time you sold one
Tijuana settled a bet, but why would you take rapamycin?
I know I'm skipping ahead a little bit.
Yeah, so let's skip ahead.
So 99, this drug comes on the market
for organ rejection.
And about 12 years later,
a study gets published
by Rich Miller, Randy Strong, and colleagues
as part of what's called
the Interventions Testing
Program, or the ITP, which is an amazing NIH-funded program that tests molecules that
are believed to have a shot at enhancing longevity. It does so in a really, really
rigorous way, probably the most rigorous way we can test small animals. I've interviewed Rich
Miller as well, probably one of my five favorite podcasts in terms of nerding out on all of the molecules that can potentially impact
longevity. And rapamycin was in many ways the poster child for the ITP program because, first
of all, it's hard to get anything to live longer. Second of all, when they were making the formulation
for the rapamycin to feed the mice, and these were
very special mice. These were not your typical crappy lab mice that have no bearing whatsoever
to real animals. These are a very special type of mice that are much more akin to real animals.
And that's a very important distinction between what happens in 99% of mouse research, which is almost inapplicable
to humans. And it's why so many drugs that get tested in these B6 mice and things like that
show some marker of success and they become wild failures beyond the mice. But this was different.
They had trouble getting the formulation to work. And by the time they finally did,
the mice were like
20 months old, which means they're almost at the end of their life. They're like 70 year old,
65 year old mice. And they contemplated just scrapping the experiment, but they were like,
eh, screw it. Let's just run it late. So they started feeding the treatment group with rapamycin
and the placebo group get to continue eating their regular chow.
Because it was oral administration.
Yes. The rapamycin was mixed into their chow. And lo and behold, the rapamycin group, despite initiating treatment so late in life, had a staggering improvement in lifespan. There's
been so many ITPs that have replicated this. I don't want to misquote it, but something to the
effect of like a 17% or 19% improvement in the% improvement in the females and 11% to 12% in the males. And remember, the ITP uses a very rigorous way of
assessing this, which is they're taking a look at total life, not just remaining life. It's an even
higher bar to clear how much lifespan elongation happens. They, of course, immediately went and
repeated the study, administering the dose when they were younger and saw an even greater response
this has been repeated over and over and over again and to my knowledge there is not a single
animal study that has tested this hypothesis that has not found this result oh that's wild
which again is very unusual yeah um so it's just replicated over and over and over it's
replicated non-stop what is also interesting is when looking at other markers other interesting
things such as vision and hearing and other markers of health span we continue to see
improvements in these things for animals as well and as i think we even spoke about before
a guy named matt caberline who i'm I just interviewed for a second time for the podcast, has been studying this in
companion dogs and looking at heart function. Because as you know, basically two things kill
companion dogs primarily, heart failure and cancer. And so the question is, what would you be
able to do to mitigate, especially heart failure, congestive heart
failure in dogs, especially large dogs, which are more susceptible to this. And again, the results,
though the research is limited because there's not an enormous interest in funding this research,
and it's expensive to fund research in dogs that live so long, it's all pointing in the same
direction. So when you contrast metformin and rapamycin, you have the opposite thing, right?
In metformin, we have tons of human data that are not randomized, but are suggesting in cohorts that
metformin is also protective, but in a subset of people that have diabetes. So it's not as clear
how protective metformin will be in people that do not. In the ITP, metformin did not succeed. In other words, metformin did not
extend life in the mice when given alone. When it was given with rapamycin, it did, but you could
argue that was all the rapamycin. I'm more bullish on rapa simply because I've been taking it now for
three years outside of- And you can hear dog whistles.
Outside of the aphthous ulcers which are the most annoying
side effect of them those are those little mouth yeah little mouth sores you get a canker sore
yeah i don't get them de novo but if i like if one of my kids head butts me which they do at
an alarming frequency um and my if i break a piece of my gum like it's going to be an aphthous ulcer although what is it called again aphthous ulcer aphthous yeah a p h t h o s yeah yeah nasty nasty it doesn't sound fun is that the
only documented in healthy normals i don't know who would fund this research if anyone would
or i don't know what i guess i don't even know what the measurements the metrics would be but well that gets to the problem we don't have a meaningful biomarker of aging
yeah i mean that's full stop the biggest problem in aging research today hands down nothing else
matters yeah when you don't have a really good biomarker for aging we're sort of sitting around
twiddling our thumbs pontificating doing studies that look at things
that aren't that interesting or things that are interesting but are like first order second order
you know but we just we can't see the whole polynomial right like if you think back to like
what a taylor series is in calculus if you're trying to use a polynomial to estimate sine x
the first order term is x equals Y. That's interesting for about
that much. But when you really want to know X minus X cubed over three factorial plus X to the
five over five factorial, when you want to really start figuring out the shape of this thing,
you're just going to need better tools. As we're talking about rapamycin, I think naturally a lot
of people listening will think of lifespan. It's a term they're more familiar with right yep start to finish what are you clocking in in terms of years
and then there's healthspan and you know i took a note as i always take notes during these
conversations about the vision and the hearing so i'm 40 i guess my memory is also going 43
and recently had a not quite an audiology test i mean it wasn't it was quite basic hearing test
and seemed to have some minor hearing loss in the higher ranges on one side could have been
some of the ambient noise in the room i don't. I'd like to try to replicate it. But could one make a compelling
argument that rapamycin could improve restoring that type of hearing? Or is that too much of a
stretch? It's just too soon to say. I think it's certainly plausible, but I think it's too early
to say. I mean, we've seen that in animals now. We've seen that in animals, but I don't know if
that's going to translate to humans. Has that been seen in multiple species? I've only seen it in mice.
In mice? Yeah. These are kind of the feral mice versus the Holstein cows of mice?
To be honest with you, I don't remember what mice were used in that study,
but it's quite possible they were your garden variety, genetically not so interesting mice.
Got it. You've hinted at or outright identified a big challenge, which is how do you study a drug in healthy people? And by the way, a drug that has a little bit of a bad
rap, immune suppressing drugs don't have people very excited. And until 2014, until Christmas day,
2014 or Christmas Eve day, I didn't think of this as very interesting. So in 2011, you have the first ITP
published and it's like, wow, that's cool. But I used to give this to kidney transplant patients.
I'm not taking that. And then you had Joan Manick was the lead author on a study that came out at
the end of 2014 that looked at a rapamycin derivative called Everolimus. And it was given
to 65 year olds in the following fashion.
There were four groups, a group that was given a placebo, a group that was given one milligram
every day, a group that was given five milligrams once a week, and a group that was given 20
milligrams once a week. And they were given this for a period of eight weeks, I believe,
and then they were taken off everything for another period of, I believe, six weeks. And
they were challenged with a flu vaccine and then looked to see who mounted the best immune response.
And counter to what you would expect, the people on rapamycin developed the better immune response,
which flew entirely in the face of what one would have expected. The group getting five milligrams
once a week, they had the best
response and the fewest side effects. So the 20, we probably don't want to go down this path because
it's just more complicated. There are two complexes of mTOR. We got to talk about mTOR.
How does rapamycin work? It works by inhibiting something called mTOR,
the mechanistic target of rapamycin. We could also refer people to our conversation with David Sabatini.
Absolutely. Back on Easter Island.
Back on Easter Island. So long story short, there was a trip. It may or may not have involved some
wine to Rapa Nui, to Easter Island. And one of our trip mates was David Sabatini, who,
cue Peter, was the first person to identify how rapamycin worked in mammals. Yeah. So we talk about that quite a bit in that episode. So I think
let's refer people to, if you just search Tim Ferriss show Easter Island, I can't imagine
there are many results and you will see an amazing crow arm displayed by another one of our trip mates
which happens to just be an artifact from a weird panoramic shot but we did use that photo just to
just to shape his nuts a bit so let's see yeah so let's just wrap that up by saying that the
five milligram dose seemed to be the sweet spot once a week it produced all the benefit without
the side effects 20 produced a similar, but had too many side effects.
Do you no longer take metformin?
I do not.
Interesting. What were some of, I know you referred to, what was his last name? Matt?
Caberlin.
Maybe it wasn't Matt. Matt Caberlin, I know. Something Miller.
Oh, Rich Miller.
Rich Miller. What are some of the other candidates that are most interesting to you in terms of pharmacological
interventions that might extend lifespan or healthspan?
There are several others that were found to have significant lifespan enhancement repeatedly.
One is Acarbose, which is a favorite of our mutual friend, Kevin Rose.
So the way the ITPs work is really cool.
Anybody can suggest a compound. So it's basically like, you know, it's like a crowdsourcing thing
where you can decide, like, I want to know if this molecule has a benefit. And as long as you
can write the proposal, which contains the rationale for why, if they buy it, like they're
going to study it. So a carbose was suggested because the idea is a carbos
prevents the absorption of starch so if you eat a pizza you can have half of it leave your body
basically without being absorbed footnote for kevin i think the ratio of donuts and beer to
a carbos does matter probably at some point oh sure yeah sure. Yeah, yeah, yeah. And you can only take
so much acarbose. I mean, it is a little hard on your gut because it's in the gut that it's
preventing the absorption. And the thinking was, well, acarbose, if it's eliminating a reasonable
fraction of your glucose, is going to be a caloric restriction mimetic or a CRM as they call them.
So let's see if that works. And it turned out a carbose did work, but interestingly, the
animals who lived longer, weren't any lighter and didn't have any lower levels of average glucose
than their shorter lived counterparts. So whatever a carbose was doing to extend life, it wasn't
through making you eat less or making you weigh less or making you even have a lower hemoglobin
A1C. It almost assuredly worked by the only other
thing it did, which was lower the spikes and peaks of glucose. It blunted those. So it spreads out
the speed with which glucose is hitting you, but lowers the spikes. Are you more bullish on
A-carbose than metformin? No, I don't think so. I would still probably put metformin as a more interesting
agent i mean a carbose first of all is just not an easy agent to take yeah i mean unless you like
diarrhea well maybe giardi is also a caloric restriction medic so um and honestly monthly
dose of typhoid fever yeah yeah exactly right um i'm always one i'm just one giardi about away from goal weight um i'm still more
more optimistic about metformin but also metformin is more of a mystery in fact our other mutual
friend from easter island nav chandel this is one of the things that he works on mr crow arms yeah
and um i'll be having nav back on the podcast probably in early 22 that was fantastic when
when there's some killer work that
he's doing on the mechanisms of metformin and we'll we'll dive back into that but there is
another drug that i think is super exciting that was recently published in the itp called
kanagaflozin kanagaflozin kanagaflozin spelt actually as it sounds with a C. And it is a class of drug known as an SGLT2
inhibitor. Rolls up the tongue. Yeah, the SGLT2I. And it's a more elegant version of a carbose
working in the kidney. So the kidney is kind of a cute organ, cute in that it's really smart. I think evolution figured
out that it would be too difficult to know all the things that are bad for you, but it's really easy
to know all the things that are good for you. So the way the kidney works is it gets obviously a
staggering amount of your circulation. Like 25% of your cardiac output is passing through your
kidneys with every time your heart pumps. And the first pass of the kidney is to take everything in your blood and dump it out.
So it's sort of like saying, I'm going to clean my drawers by throwing everything on the floor
and then only putting back in my drawers the things that I want. And because again, it's easier
to know you need glucose, you need potassium, you need magnesium,
you need sodium, as opposed to this toxin that might appear 100 years from now or a million years from now.
So in the reabsorption process, canagliflozin blocks the reuptake of glucose.
So you end up peeing out a lot of glucose.
So this drug obviously was introduced to treat people with type 2
diabetes, and it showed remarkable efficacy in doing that. So in a healthy subject, you would
be presenting the sort of traditional old-fashioned symptoms of diabetes. Yeah, although not quite to
the same extent because it's sort of gradient driven.
So in the traditional Osler sense where, you know, literally diagnoses of diabetes was made by tasting the urine and seeing how sweet it was, those were patients that were presenting with,
you know, wildly uncontrolled diabetes with a glucose of like 800 milligrams per deciliter.
You know, they're about to have a coma. I first learned what diabetes was when I was in Japan as an exchange student.
And it's tolnyobyo, which is sugar urine disease.
And it's really obvious in the characters.
I had no idea what diabetes was.
I heard it on the oatmeal commercial.
Which is interesting because I'm guessing nobody in Japan actually has diabetes.
Today.
Today, when you have people eating rice with mayonnaise, slightly more. When you were there, yeah, there's probably five people with diabetes. Yeah, today when you have people eating like rice with mayonnaise, slightly more.
When you were there, yeah, there's probably just like five people with diabetes.
Yeah, very few.
So, canagliflozin basically blunts this reabsorption of glucose, very successful drug for the treatment
of diabetes, and also in people with diabetes is showing better effects when it comes to
heart failure, better effects when it comes to heart failure, better effects when it comes to
mortality. This is really, in my opinion, a first-line drug for any patient with diabetes,
and it does not cause hypoglycemia. So if a normal person takes it, they're not going to have
a dangerous drop in blood sugar. So it is also blunting the spikes, but it also seems to lower
the average as well.
So Kanagaflozin extended the lives of mice in the ITP.
I don't remember the exact numbers.
It wasn't quite as- Were these diabetic or sort of-
No, no, they were not.
These are perfectly normal mice.
It wasn't as big in effect as rapamycin, but it was bigger than most other things.
There haven't been that many successes in the ITP.
Obviously, most drugs fail. But the successes like rapamycin, 17-alpha estradiol, canagaflosin, acarbose, those are some of the
big successes. And of course, they get tested over and over again to make sure they weren't
one. What was the 17-something or other that you just mentioned? 17-alpha estradiol was a very
interesting molecule. 17-alpha estradiol. Which is not the estrogen. It's not
normal estrogen, which is beta estradiol. And 17-alpha estradiol only improved lifespan of
male mice. It had no impact on female mice. The thinking being that it somewhat mimicked the
estrogen protection benefits in a male, but not in a female because they already had estrogen.
Yeah, that's super interesting. Yeah. That's not a molecule that to my knowledge is even in clinical
trials like i don't even know if there's an ind for that molecule that it's even i don't know
what pharma is doing with that information how did that get submitted for the itp yeah it's funny i
asked rich about that i'm just backyard chemist who's like yeah it was
it was i inherited a bunch of oil money here i want you to make no it was effectively someone
who had been studying this molecule and thought like i wonder if this would be interesting for
the hypothesized mechanism that it would offer some of the protective benefits of estrogen without
the feminizing effects right so it's it doesn't have the sexual characteristics of estrogen so
the question is because if you gave a male a whole bunch of estrogen you're not going to make them
live longer yeah because whatever benefits come from it are going to be offset by a bunch of
negatives just to scratch my own itch in curiosity here so can someone with enough money just push
whatever they want through the itp to get something tested or like what combination of factors
leads someone to be able to take a candidate or something they think is promising, like a 17 alpha
estrogel. It's not about money. I think honestly, it's just about having the time. Like there's a
candidate drug that I'd like to put on and I just haven't had the time to write a proposal.
So maybe in a couple of years, when I finish the book and a few other projects,
yeah, there is a candidate that I think would be interesting. So no, it's just having a good
scientific case for it. Yeah. That's fascinating. Should we do some stupidity, I think? Absurd
things. Anything particularly ridiculous that you're doing these days or enjoying?
I think with the lockdown, with the
whole COVID thing, I've never spent more time at home and it's been amazing. Like it's been-
It's your dream come true.
Oh, it's just like, take the most antisocial person in the world and allow him to never have
to go out. And that's been, I think, really great for my family on some levels, but also it's mean
that they've, it meant they've had to put up with more of my stupid jokes and the, like just the dumb things that I think about.
So one of the things that I have been really harping on and just drives my wife nuts is,
you know, when you eat a banana at the very bottom, there's that little nubbin,
yes. You know, the little part. So I am convinced that the nubbin is like lethal. Like if you eat a nubbin, you're going to die.
And so I'm the nubbin police of our house because a lot of times, you know how you can
never finish bananas?
Like you buy them, you buy like 10 and you might eat three, but then seven are going
to go bad.
So we peel the bad ones and put them in the freezer to make smoothies later on because
we always add frozen fruit to make smoothies later on because we always add
frozen fruit to make my protein shakes or whatever. When I do it, I'm really careful to
never put the nubbin in. I peel it, but I keep the nubbin in the peel and it goes in the trash.
But when my wife does it, she just leaves the nubbin in. Of course, I don't care, but I act
like I care. I'm like babe are you serious
got a nubbin in here like there's people in the house they could eat this like do you understand
the nubbin is literally the third leading cause of death worldwide not in the developed world here
it's like the fifth leading cause of death but when you average it out across the globe third
leading cause of death nubitis nubitis so and it just doesn't get old to me i think the more it bugs her the funnier it is
to me and the same with my daughter just endless eye rolls and the nubbins they don't buy it they
really think they claim that you can eat a nubbin and nothing will happen to you depends on your
topo chico to nubbin ratio in the house i think you're pretty heavily weighted in the former
all right what else do we have on any of the three categories?
Really?
If there's something that jumps out where you're like, this is really for any reason
pulling my attention.
Let me look at my list here and see what else.
Oh, I know something else I've changed my mind on.
Yeah.
I'm way, way, way more bullish on sauna than I have ever
been before. I used to be in the camp of sauna feels great. It maybe even helps you sleep a bit
better, but that's probably about it. There's no way you're going to really live longer because
you're in a sauna. While truthfully, we don't have really great prospective data, or sorry,
I should say we have good prospective data, we don't have good randomized data.
I think this is one of those things where the burden of evidence in the non-randomized data is so strong, it's becoming hard to ignore.
So most of the research on this subject has come out of Finland.
The sauna lobby. Yeah.
And so there's the obvious issues with this, right? The people who can afford to sauna
are by definition going to have more time on their hands, more disposable income,
probably more education, like all of the standard things. On top of that, if you're going to choose
to sauna because you believe it's
healthy what else are you doing because you believe it is healthy i mean right so if the data showed
that sauna versus non-sauna was like a five percent improvement in mortality it would be hard to get
that excited about it but when you look at the largest published series on this, you see a benefit in all-cause mortality,
a relative risk reduction of 40%, and an absolute risk reduction of like 18%.
Those are-
Those are high numbers.
Those are ridiculous numbers.
And that's when you are comparing someone who like saunas four to seven times a week i was going to ask yeah so
what's the dose and frequency what's the yeah yeah what's the dose and frequency and what do
you believe the minimum effective dose to be kind of like the zone two training you described what
it is and then you said that degrees celsius four sessions times 20 minutes
80 degrees celsius oh you you're fahrenheit what's the conversion there i should be better It's about 175 Fahrenheit. 175 Fahrenheit. Got it.
Dry, wet.
There's much more literature on dry.
I actually had a call with a patient this morning, and this topic of saunas came up.
And she asked if she could substitute steam rooms and such.
And I said, we just don't know because we don't have the data.
So the precautionary principle would say, if you have access to a dry sauna, that's where
we have reams and reams and reams of data.
So it's probably where it goes.
But look, if you think about what the mechanism of action is.
Yeah, I was going to ask you next.
Is it heat shock proteins?
Is it something else?
I think it's many things.
I think it's heat shock proteins.
I think it's nitric oxide.
I think it's literally vascular tone, right?
Reduction in blood pressure, increase in heart rate and cardiac output. So there's a bit of an exercise benefit. I think
BDNF has been measured. I can't recall. That could be another potential benefit. So my guess is-
BDNF, brain-derived neurotrophic factor.
I think it's probably half a dozen things that are all moving in the right direction.
It's funny, when I have done some sauna ing i've
done lactate checks in there to see if it gets me to zone two it's not a pure exercise memetic
because it doesn't even get me to the level of a zone two workout at least when it comes to a pure
atp uptake or atp production standpoint but yeah i've become really optimistic on this and i think
it's very promising and i think it's again again, the challenge is how scalable is it, right?
Like it's not that easy to do.
I would imagine also contraindicated for a lot of folks.
Yeah.
Depending.
Yeah, I suspect.
If you're really far down the line of your health is suffering and you're particularly old or something like that, or your heart's a little more frail, yeah, this might push you a little bit beyond. So again, it speaks to sort of prevention and
hopefully with COVID kind of winding its way down and enough people getting vaccinated,
people can get back to gyms where saunas are and things like that.
Yeah. Amazing. Preferred method for zone two training? It seems like you do most of your
work on a bike. I do. I like the bike. It's just my body is so much more efficient on a bike than anything else do you have a preferred stationary bike or do you yeah i do i
ride my bike like my road bike on something called a wahoo kicker wahoo kicker which is awesome like
hands down if someone doesn't have a road bike then i my favorite stationary bike is the kaiser deck heisa no i don't think that's
actually the sosa k-a-i-s-e-r yeah k-a-i-s-e-r i believe all right and i think kaiser makes such
a fantastic spin bike you want to do one more change your mind about or one more excited you
can uh dealer's choice yeah i'm pretty excited about glp1 agonists
me too i don't even know what that means tell me peter all right so glp1 agonist glucagon like
peptide one they also go by glp1 ras soucagon-like peptide 1 receptor agonists. Okay, so glucagon is a hormone.
It's made by the liver, sort of opposes the action of insulin. It's a hormone that produces satiety
and can regulate blood glucose levels. Regulate, meaning it's catabolic?
Lowers blood glucose. It secretes insulin
actually. It results in secretion
of insulin to lower blood glucose.
So these are a group
of drugs that have been around for
quite some time. Also a
high choice in people with type 2 diabetes.
A trial came out
I want to say 2014
showing
that one of these drugs was actually also pretty good for weight loss in non-diabetics
it didn't get a lot of traction the effect size was was reasonable but it wasn't great
i looked at it quite a bit because i remember at the time i had a patient whose weight was
really recalcitrant it just wasn't clear what it was going to take to
help her lose weight. And I certainly am not a fan of stimulants for weight loss. Drugs like
Phentermine can be somewhat effective, but they can also have their side effects and be somewhat
habit forming. And we had sort of noodled this and eventually we ended up trying this drug.
It didn't really have that much of an effect.
And I kind of sort of put it aside for a while until about six or seven months ago, I was
talking to someone who had an early line of sight into a trial that was going to be published.
And they said, you know, they'd been using it clinically, a newer version of this drug.
It's called semaglutide.
The trade name is Ozempic.
And they said, yeah, you've got to see what this drug can do.
So the drug, the dose that's given for people with diabetes is one milligram once a week.
So it's an injectable drug.
So it comes in a little pen.
You shoot it in your gut or your leg once a week, one milligram.
Is it intramuscular or subcutaneous?
Tiny, tiny little insulin syringe. And he said, yeah, but when we push people up to two and a
half milligrams, the weight loss is comical. This is not just people with diabetes. This is anybody.
And then sure enough, there was a study that was published probably a couple of months ago,
looking at semaglutide in overweight and obese people without diabetes and the weight loss was through the moon
i mean it was you know we're talking like 20 weight loss holy shit completely durable as long
as you're on the drug so then it begs the question what happens when you come off the drug we haven't
seen fully what that looks like yet i mean i think we need to see what those studies look like i mean
my thinking of this we've now put a lot of patients on this drug. A lot is relative, but maybe 12,
15 patients we've put on this drug. Some people can't tolerate it because of the nausea.
Nausea?
Yeah. I mean, that's definitely one of the side effects.
How often is it administered?
Once a week.
Once a week. Is the nausea transient or is it?
Yeah, it tends to fluctuate. So if you
inject it on a Sunday and then, you know, usually by the next Saturday, the symptoms are gone. But
then when you hit yourself on that Sunday, Sunday, Monday, Tuesday, you'll be a bit more nauseous.
Now, again, that's so it's transient across the week, but it also seems to be transient over time.
So the dose in the study was 2.4 milligrams. So, you know, two and a half times higher than
you're doing it in people
with type 2 diabetes but you don't start people at that dose you'll start them at half a milligram
for a few weeks then one milligram then one and a half then two etc but basically we haven't seen
any patient who can tolerate the drug that does not lose weight have any cycled off in which case i mean obviously behavior matters a lot and calories
matter a lot but yep do you see a greater rebound than you would anticipate otherwise and they don't
seem to regain all the weight they lost now my biggest concern i was so fascinated by this before
the study came out we actually did a whole journal club just on this study
and went stupidly nerdy on this drug.
The biggest concern I would have is,
is a drug that lowers glucose but raises insulin such a good idea?
Yeah.
And also, it flies in the face of how you would lose weight in that situation, right?
It seems to not be entirely clear why
would that result in weight loss unless the increase in insulin along with the glucagon-like
peptide are reducing appetite. But what we've discovered in experimenting with a lot of our
patients, by experimenting I mean just doing a lot of blood tests before and after, is while it
probably slightly increases your fasting insulin level, it's also clearly increasing muscle insulin sensitivity because postprandial insulin levels seem to be down.
And I would bet, though it was not done in this study, I would bet that if they had looked at 24-hour insulin secretion, which you can do by collecting 24 hours of urine and measuring C-peptide,
which exists in a one-to-one ratio with insulin. Because when insulin comes out, it's a pro-hormone
and then it gets cleaved into insulin and C-peptide. So you should have one C-peptide
for every insulin. So if you measure the urinary amount of C-peptide, you know how much insulin
was secreted. I'm really disappointed that study didn't do that, but my guess would be that they saw 24 hours C-peptide go down even as resting insulin went up.
Okay, which would mean, and well, please correct me if I'm oversimplifying this, but that on,
if you look at the average, it is not net-net leading you to increased insulin levels.
That's right. Yeah.
That's so interesting.
Now, when you say 20% reductions,
are we talking about body fat or body weight or?
Body weight.
Wow.
Total body weight.
Yeah.
Wow.
So, you know, that's, and that's easy.
You'll see more.
Yeah.
These are in obese people.
Yeah.
We've even put it, we've even had patients who are not even,
wouldn't be classified as obese, just slightly overweight. You know, a 200 pound person that in three months
is 180 pounds and effortlessly at 180 pounds, right? Like they've literally reduced their
appetite and they've improved their insulin sensitivity and glucose disposal. And that's
where other interventions failed. So it's not, I mean, I know we're not blinding this or anything with patients,
but you attribute that predominantly to this drug, not to, say, changes in eating or other habits.
Well, they have changed their eating, but I think it's in response to the drug.
Yeah. So I think the drug is working centrally, peripherally. I think it's working
on the fat cells. I think it's working on their brain. I think it's working on their muscles. I
think it's doing a lot of things and it's still early days, but I mean, this is a promising drug
in my opinion. And I think there's some people who think that you shouldn't need a drug to help you.
And if you need a drug to lose weight, you're somehow a
bad person or something like that. But I just think categorically, that's just such a simple
minded view of the world, right? We live in a world with technology. And just as you don't rub
two sticks together when you want to have a fire, if a Zippo lighter is available to you, if you
have tried every dietary strategy imaginable and your metabolism is not,
you know, moving in the right direction, why shouldn't we explore other ways to kickstart that?
And the other thing, by the way, is I think you can take these things for a few months,
come off them and see if you have formed new habits in the interim. I also think there'll be,
in my mind, a model for cycling three months on, three months off, three months on, three months
off. Again, we want to make sure that that doesn't cause some recalcitrance to the medication or
something like that but i think this is exciting i think this warrants a lot more follow-up but
what it's saying is that things that improve diabetes also improve health and nothing does
that more than exercise and nutrition that's the the reality of it. But not everybody can do enough exercise and the right nutrition with enough ease to get
the benefits.
So the more tools we have in our toolkit that go outside of that, the better.
Dig it.
Peter, always so fun to hang.
And I want to underscore to me how exciting and interesting it is for people listening
to strive to increase their scientific literacy.
And you have your series of articles, which we'll put in the show notes.
There's a book that I enjoyed tremendously called Bad Science by Ben Goldacre, who I
believe is an MD, and enjoyed that so much that had a few
excerpts from that book put into the appendix or the appendices for our body because I wanted to
provide some basics. Are there any other resources or recommendations for folks who
want to improve their ability to separate fact from fiction, hype from reality when it comes to
headlines, media, studies, and so on. I mean, not to get to Peter Atiyah level,
but to get to the point where they just have a better ability to separate signal from noise
with this kind of thing. You know, there's a good newsletter that I subscribe to
out of the University of Indiana. It's called the Metabolomics and Energetics or Metabolism
and Energetics. It's like a weekly newsletter that comes out on Fridays. And it's, you know,
it's pretty detailed, but one of the sections is always headline versus study. And that's always
a cute one because every week you get to see, they just pick one example because of course there's a billion examples every week of how the headline says something and it turns out to have nothing in common with the study.
Now that's not exactly the question you've asked, but it is a good illustration of just how, if you read something in the media, you should just assume it's being taken out of context and it's incorrect.
And unfortunately, I wish i had better answers on well it'd be like if you saw a headline that
eating nubbins increases risk of colorectal cancer by 100 but if the chance is one in
10 billion people and it goes to two and 10 billion people it's a rating doesn't mean you
should pay attention to that's right and that's not to discredit your nubbin theory but that's
a great example of always knowing absolute risk versus relative risk it's
exactly it's exactly like the kind of stuff we talk about in studying studies is never pay
attention to relative risk without knowing absolute risk as well and things like that so yeah
peter i think it might be time for us to prepare for our uh prand adventure. That's probably not the way you use it.
To have our meal.
To have our... Our pre-prandial exploration.
Our pre-prandial exploration of various cacti.
Is agave considered a cacti?
Well, I guess...
What is mezcal actually made from?
Is it agave?
I know it's like a campfire in your mouth,
but that doesn't tell us much about the botanical
origins i know satole is different have you had satole as a side note it's a plant or i should
say it's also it's a beverage maybe it isn't a plant but it's only found in a few parts of texas
and mexico and it's sort of in between tequila and mezcal speaking of texas can i tell you the only thing so far about texas i'm not fond
of uh scorpions in your kitchen i've only found that was that was this morning in my household
took care of it was fine it's the cactuses when i'm out in the bush so when i was out what are
you doing out in the bush well when i was out doing that precision shooting a couple months ago they were like training for your counter sniper operation
that's right so we had like mats down on the ground and we're laying on our mats and we're
shooting off in the distance and i i vaguely remember someone saying stay on your mat oh god
and um so at one point i'm like loading my magazine and I kind of rolled off the mat and, you know,
loaded it and was shooting. And then like that day we're driving home and I'm like, God, why does my
butt hurt so much? And why does my leg hurt so much? And, you know, by the time I got home,
I realized I was just full of these little micro needles. And I mean, this is how, you know, your wife really loves you because like I
had to give her a set of tweezers to literally start yanking these needles out of my butt and
my leg. And I actually still have some there three months later. I still, I can still feel
some of the ones that broke beneath. And, and so I'm going on this hunt in about three weeks and
it's my first time hunting axis deer
here in texas and one of the things that the guy who's taking me said is you you got to make sure
your shoes like the cactus is one go through your boots you're not going to wear your ninja socks
for this one yeah no this will not be a barefoot hunt but aside from the cactuses man yeah yeah
all good in the republic of texas i have a shirt
maybe i'll get you one of these you might have seen it it says has a big flag texan flag on it
it says most likely to secede yeah they saw those at the airport in austin for those who are
interested well peter off to dinner we go thanks again is there anything that you would like to
mention before we close?
Of course, people can find you.
Peter Attia, MD will basically take them to everything, I would imagine.
That's the website.
That's Twitter.
It's Instagram.
That's Facebook.
Also YouTube.
So you've been very consistent with how people can reach you.
The podcast is The Drive, which, which as mentioned is a weekly deep dive podcast
focusing on all of the nerdy subjects that i find so fascinating that peter and his guests
know so much about anything you'd like to add to that i mean i would just say that some
decaffeinated brands of coffee are just as tasty as the real thing you know what their reference
is what movie is that from i don't't get the reference. What is that? Is that real genius? I think it's real
genius. Is that real genius? I think so. I'll give you a bit of Austin trivia. We're going all
over the show here, but there is a food truck here in Austin, which I had been told by a former
professional tennis player. I had to try it. It had the best chicken wings. And for me, the chicken wings in general are kind of like the pistachios of the fowl family. They're just
so much work and you just don't get much out of it. Turns out Tommy Want Wingy, which is the name
of this food truck, has incredible chicken wings. They're delicious. I don't know what
anabolics they give these chickens, but're enormous you can have a full meal and
tommy want wingy where's he tommy want wingy do you know he's he's actually at i think it's cosmic
cafe they may have multiple locations do you know what reference tommy want wingy is from
well it's not the donger need food that's 16 candles tommy boy chris farley tommy want wingy the diner scene it's funny i've
seen that movie a hundred times how have i missed that oh yeah yeah he's talking about his sales
process and he convinces them to the the waitress to fire up the kitchen after they've closed
and he grabs i think it's like a muffin and he he's like, let's say it's my prospect. And he walks through this entire thing.
We'll link to this video in the show notes.
So that for people who want us to get Chris Farley plus Zone 2 training plus rapamycin in one place.
This is probably the only site on the internet that will have all of those in one set of show notes.
And Peter, thanks for taking the time man thanks man
so does that training fall into the aerobic efficiency category exactly efficiency i don't
want to take us off of where we are too much in the sense that i don't want to create a breakaway
but could you just briefly explain what efficiency
means within the aerobic efficiency and then come back to the zone two training?
Yeah, it comes down to basically substrate usage. So in aerobic activity, you can use
glucose or fat. Those are basically the two fuels that the body with oxygen can turn into ATP. So aerobic, most people will
recognize means with oxygen and anaerobic means without oxygen. So when you're not demanding much
energy of yourself and energy, of course we talk about is ATP. So ATP is the currency for energy. When your body isn't demanding much energy, you can make ATP
using glucose or using fatty acids. And it's a similar process, but obviously different because
they're different molecules. So glucose gets turned into something called pyruvate, and that
happens in the cell, but outside of the mitochondria. And then the pyruvate gets shuttled into the
mitochondria where it undergoes a process known as the electron transport chain where a whole
bunch of chemical reactions occur that basically generate a gradient of electrons in the inner
membrane of the mitochondria that's ultimately used to produce carbon dioxide and water and a boatload of ATP.
With fatty acids, it's a little different. Fatty acids get broken down into smaller chunks of fatty
acids that have two carbons called acetyl-CoA, and the acetyl-CoAs get fed into the mitochondria
and undergo the same sort of process. So what's nice about that is you have the ability to use both fuels, but when energy
demands start to climb, so when you are asking more of yourself, when you're now running or when
you're walking up a flight of stairs or doing anything that now the body's saying, hey, I need
more and more ATP, that glucose system is the first one to cave. So the glucose system, when
you turn the glucose into pyruvate, it basically
says, I don't have enough oxygen to run this through the mitochondria to do what I need.
I'm going to instead turn pyruvate into lactate, which yields some ATP, but a pittance compared to
what it could do. So pyruvate into lactate will generate one-sixteenth the ATP that it would if it went into the
Krebs cycle, which is horrible, but it's like any port in a storm. It's like, I don't have a choice.
As a side note, everybody tends to think that lactate is what causes the soreness when you're
doing that. It's actually not the lactate. It's the hydrogen ion that accompanies the lactate
because lactate is acidic. So you don't actually feel anything from the
lactate and lactate itself is actually a pretty remarkable fuel the brain there's emerging evidence
that the brain actually likes lactate as a fuel and the liver can turn it back into glucose pretty
easily but nevertheless it's inefficient it's a horrible way to turn your hydrocarbon into atp
and it does come with this problem of being self-limited. So the efficiency speaks to the longer you can use the mitochondria, the better.
And this zone two characteristic is really one of the most remarkable ways to separate
and differentiate people with different degrees of metabolic efficiency.
So Inigo San Milan and George Brooks did a study that I talked about at length in one
of the AMAs.
Did you say Cesar Milan? I'm kidding. It's a dog trainer. What were the names again?
Inigo, San Milan, and George Brooks. Inigo has been a guest on my podcast as well. They did a
study looking at three cohorts of people, professional cyclists, fit people, and people
with type 2 diabetes. Just real quick, how did they define
fit? I don't remember exactly, but it would be like people who exercise a certain number of
hours a week who were pretty fit. These were people that were probably exercising 10 hours
a week or something to that effect. So not just kind of like weekend work. 10 hours a week is
non-trivial. No, no, not at all, right? And what they looked at was what were their lactate curves on a bicycle, and at what point
did they reach that two millimole level?
You know, it's just a staggering difference.
So all of them would ultimately achieve high lactates, admittedly very different powers.
The fitter you are, the more power you generate before you hit that peak lactate. The people with type 2 diabetes were reaching this critical threshold at something in the
vicinity of 80 to 100 watts. So 80 to 100 watts on a bike, if you don't know what that feels like,
it's hard to explain what that would... I wish I had a good conversion for what that feels like.
That's not a lot of effort. I guess for someone who spends any time on ground, slight incline, flat ground,
no wind going 13 or 14 miles an hour, maybe less, which amounts to about 1.2 Watts per kilo.
Cause you always want to normalize these things to body weight. So 1.2 Watts per kilo,
one watt per kilo in that vicinity. The reasonably well
trained person was hitting that number at closer to 150 to 170 watts, putting them pretty comfortably
in about the 1.7, 1.8 watt per kilo range. So significantly higher than people with type 2 diabetes. And the professional cyclists were hitting that mark in the vicinity of 320 to 360 watts. And of course, they're even lighter. So they're hitting
that number at a staggering four watts per kilo. What was the total duration of the assessment?
It's typically done unlike a ramp test where you're quickly, quickly changing. You
typically do long ramps. So 15 minutes, check lactate, 15 minutes, check lactate, or 10 minutes
would be about the minimum. Do you think those results would have looked different had the muscle
groups involved been different? Had it been like a hand bike or something like that? I guess I'm
wondering if there's any localized effect just given the training of the cyclists. Yeah, it's possible.
And certainly there's an efficiency that comes from doing the thing that you're being tested on.
Typically, lower body exercises are the way to do this because we have so much muscle mass there.
When we have patients do their zone two, we basically recommend three things.
A bike, a rowing machine, or a treadmill are probably the best ways to get that.
And it doesn't have to be running.
I mean, when I do...
Now to get, you mean to assess or to also train?
Both.
Both.
Yeah.
Because it does need to be pretty steady state.
Hiking up and down steep climbs tends to not be a great form of training for this.
That's another type of training. But when you're coming in and out and in and out of zone two, it's not the same
as sort of planting yourself there, staying there and forcing your mitochondria to adapt to it.
That was actually going to be my next question. So what is the adaptation that one hopes for?
What is actually happening to the body when you do effective zone two training. So you're increasing
the ability of the mitochondria to utilize the substrate. You're increasing the ability of the
muscle to actually take in more oxygen. So it's really funny when you compare a really fit person
to a really unfit person. And so think about something like a VO2 max test.
Everybody's breathing the same amount of oxygen. So let's imagine for a moment that you are
the fittest guy in the world and I am not. We're both sitting in this room. We're both
breathing in 21% oxygen. If you then put us on a bike and make us go as hard as possible
and measure how much oxygen is coming out, you'll notice that much less oxygen is coming out of you than me.
So the difference is you're able to use more oxygen than I am.
And that is probably not mediated at the level of your lungs.
That's probably more mediated at the level of your muscles.
Now, there may be some differences in the lung as well. This is not an entirely settled question, but there's undoubtedly a bigger delta
at the muscles. So that's a big part of it is simply being able to utilize more oxygen. The
other thing is perhaps increasing the density of mitochondria. So simply having more mitochondria
in the muscle will allow for more of that substrate to enter the mitochondria versus outside.
And then, of course, there are transporters.
And the transporters determine a little bit of how the body can sort of utilize lactate, keep it in the cell versus recycle it and get it out of the cell quicker.
From a training standpoint, the good news is all of this stuff is trainable, but it does require deliberate form of training. And one
thing I don't think we know yet, but it's looking like the minimum effective dose is probably about
three hours a week, ideally delivered at sort of 45 to 60 minute intervals. I've asked Inigo about
this specifically, you know, would, would just as
a thought experiment, would doing a whole bunch of 15 minute sets a week be sufficient? His view
is it would not be that it probably needs to be at least 45 minutes per session. So you could do,
I do four 45s these days as my zone two protocol. At times I've've done more there's times i'm doing four 60 minute sessions
a week and those should feel if i'm remembering correctly from what you said earlier those should
not feel agonizing no these should be kind of sustained all-day hike type of i know hike isn't
exactly perfect but assuming it's a, say, flat ground
constant load, this should be something you could sustain for much longer than, say, 45 minutes.
That's right. And not all of our patients want to use a lactate test. So I lactate test myself
every time I do a zone two test. So I have- So unlike you, Peter.
Right, right, right. So for three years, I have every session I've ever done recorded by power,
heart rate, lactate, all of that stuff. Because you do see variation, by the way. So a given power doesn't always keep me at the same zone too. So how well I slept the night before,
my state of hydration, what I've eaten will all impact this.
How are you tracking whether you are in zone two or not?
By poking my finger.
By lactate.
Yep, I'm using that.
Okay, so when people don't want to do that, what do we recommend?
Well, we recommend figuring out what your zone two heart rate is because you can track
heart rate really easily.
So rectal probe most of the time?
Exactly.
No, that's for temperature.
So heart rate-
Depends on how long it is, right?
Yeah.
Just sitting right there on the vena cava so with heart rate you want to give somebody a starting point so one option is you tell people to do a little bit of lactate testing maybe test yourself
once a month figure out what your heart rate is and then going forward just rely on heart rate
for people who never ever ever want to poke themselves or just are insulted by how expensive
these stupid things are, which they are really stupidly expensive. Like the lactate meter is
250 bucks, but the strips are $4 a piece. So, which is just so aggravating because you know,
these things cost about 12 cents to make. We usually use two ways of estimating. One estimate
is 180 minus your age, which I think
is the low estimate. So a 50-year-old, you'd start them at about 130.
130 what?
Beats per minute.
Beats per minute.
Another way to estimate it is if you know your maximum heart rate. So this is usually for people
who exercise quite a bit with a heart rate monitor, and they know what their true maximum
heart rate is. So let's say a person's out there and they say, you know what, I can achieve 178
beats per minute just before I feel like I'm going to keel over. That's your max heart rate.
I usually start people at about 78% of max heart rate. Now, again, the next thing we layer on that is the litmus test of how do you feel?
Are you able to almost carry out a conversation when you're doing the activity? And the answer
should be yes, but I don't really want to. That's about the sweet spot.
It's a strained conversation, but you could do it.
Yeah. Yesterday I was doing my zone two and my dad called and I'd missed a bunch of his calls. Normally I don't answer the phone when I'm on
the bike because I have a fan that is blowing air on me so much and it's so noisy, but I answered
the phone anyway. So, you know, I talked to my dad for five minutes, which mostly meant I let him
talk and I was kind of like grunting a little bit. Yeah. Uh-huh. Yeah. Okay. Yeah. Uh-huh. Uh-huh.
But I wouldn't want to do this on my bike for a zone two.
Like this would be a bit more than I'd want to do.
And if you can't talk at all,
which you wouldn't be able to talk, of course,
if you're doing like a zone five,
then you're obviously going too hard.
The long-term benefit, just to reiterate,
the long-term benefit of doing zone two training
for say a minimum effective dose of three
hours per week is what?
And when can someone expect to start to see adaptations that are beneficial?
Well, the latter is a good question because it probably depends on from where you start.
With someone who's starting out really metabolically broken, which by definition is what type two
diabetes is, that's the most extreme example we have of completely broken metabolism, right? So a complete inability to partition fuel,
almost a complete inability to burn fatty acids, which again gets back to your question about
efficiency. An efficient engine should be able to run on two fuels. It should be able to run
on glucose and it should be able to run on fat. A broken engine can only run on the short-term fuel, which is glucose. That's a brutal cycle to be in. If you can only run on glucose,
you're going to be in a tough situation because we can store such a tiny amount of glucose relative
to fat and you're going to be at the mercy of fluctuating glucose levels constantly. Whereas
if you can rely on fat, you're better off. I've seen people make adaptations to this.
I would usually say it takes three to six months to start to see some adaptations.
I guess over the past two and a half years, my zone two power has gone up by
25%. Power measured by watts yeah and to be honest it's still below what it was
nine years ago or seven years ago when i was training as a cyclist so even though i didn't
think of this type of training as a cyclist i would do these types of workouts as an important
part of my overall training and I was just infinitely fitter back
then. So my zone two back then was probably 40 Watts higher than it is now. Although my zone
two is probably 40 Watts higher now than it was two and a half years ago. Hey guys, this is Tim
again. Just a few more things before you take off. Number one, this is five bullet Friday.
Do you want to get a short email from me?
Would you enjoy getting a short email from me every Friday
that provides a little morsel of fun for the weekend?
And Five Bullet Friday is a very short email
where I share the coolest things I've found
or that I've been pondering over the week.
That could include favorite new albums that I've discovered.
It could include gizmos and gadgets
and all sorts of weird shit that I've somehow dug up in include gizmos and gadgets and all sorts of weird
shit that I've somehow dug up in the world of the esoteric as I do. It could include favorite
articles that I've read and that I've shared with my close friends, for instance. And it's very
short. It's just a little tiny bite of goodness before you head off for the weekend. So if you want to receive that,
check it out. Just go to fourhourworkweek.com. That's fourhourworkweek.com all spelled out and
just drop in your email and you will get the very next one. And if you sign up, I hope you enjoy it.
This episode is brought to you by Aura. O-U-R-A. It is the only wearable that I wear on a daily
basis. Aura is the company behind the
smart ring that delivers personalized sleep and health insights to help you optimize
just about everything. And I've tried every device out there that you can imagine.
This one really makes the cut. I've been using it religiously for at least six months now,
and I was introduced to it by Dr. Peter Attia, who's also vetted just about everything. With advanced sensors, Aura packs state-of-the-art heart rate,
heart rate variability, HRV, super important to me, temperature activity, and sleep monitoring
technology into a convenient non-invasive ring. It's tiny. It weighs less than six grams and
focuses on three key insights, sleep, readiness, and activity. So I can use it to help
focus my attention on the type, volume, intensity of exercise that I should do in a given day.
I use it to determine how certain types of alcohol at different times of the day affect
my sleep, which they do. And I can see all of that in graph form trended over time.
There are tons of actionable insights that have come from using this ring for me. They have a number of incredible people on their team. Dr. Matthew Walker,
the professor of neuroscience and psychology at UC Berkeley, and also author of Why We Sleep,
the mega hit, is Aura's chief science advisor as just one example. The Aura ring is one of the most
accurate wearables available because it
measures your vitals directly from your finger. So it's not deducing that or making a best
guesstimate based on a bunch of other things and trying to triangulate. Compared to a medical-grade
electrocardiogram, the Oura Ring is 99.9% accurate for resting heart rate and 98.4% accurate for
heart rate variability. And I work
with HRV doctors and they recommend that I use the Oura Ring. So try it yourself. It is super cool
and super practical, very actionable. The Oura Ring comes in two styles and three colors,
silver, black, and matte black. I use matte black. For $299, you can give or get the gift of health by visiting
OuraRing.com. That's O-U-R-A-R-I-N-G.com. Again, that's OuraRing.com.
This episode is brought to you by Eight Sleep. My God, am I in love with Eight Sleep. Good sleep
is the ultimate game changer. More than 30%
of Americans struggle with sleep. And I'm a member of that sad group. Temperature is one
of the main causes of poor sleep and heat has always been my nemesis. I've suffered for decades,
tossing and turning, throwing blankets off, putting them back on and repeating ad nauseum.
But now I am falling asleep in record time faster than ever. Why? Because I'm using a simple device
called the Pod Pro Cover by Eight Sleep. It's the easiest and fastest way to sleep at the perfect
temperature. It pairs dynamic cooling and heating with biometric tracking to offer the most advanced
but most user-friendly solution on the market. I polled all of you guys on social media about the best tools for sleep,
enhancing sleep, and Eight Sleep was by far and away the crowd favorite. I mean,
people were just raving fans of this. So I used it and here we are. Add the Pod Pro cover to your
current mattress and start sleeping as cool as 55 degrees Fahrenheit or as hot as 110 degrees
Fahrenheit. It also splits your bed in
half so your partner can choose a totally different temperature. My girlfriend runs hot all the time.
She doesn't need cooling. She loves the heat and we can have our own bespoke temperatures on either
side, which is exactly what we're doing. Now for me and for many people, the result, eight sleep
users fall asleep up to 32% faster, reduce sleep interruptions by up to 40%, and get more restful sleep overall.
I can personally attest to this because I track it in all sorts of ways.
It's the total solution for enhanced recovery, so you can take on the next day feeling refreshed.
And now, my dear listeners, that's you guys.
You can get $250 off of the Pod Pro cover.
That's a lot.
Simply go to eightsleep.com slash Tim
or use code Tim. That's 8, all spelled out, E-I-G-H-T, sleep.com slash Tim, or use coupon
code Tim, T-I-M, 8sleep.com slash Tim for $200 off your Pod Pro cover.